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Human immunodeficiency virus type 1 (HIV-1) relies on a handful of essential enzymes for replication. 
Among these, the viral integrase enzyme (IN) plays a pivotal role in the viral life cycle by catalyzing the 
integration of the reverse-transcribed viral DNA into the host chromosome. While integration is the 
canonical role of IN, new research has uncovered an additional vital role for IN during virion 
morphogenesis. This dissertation elucidates how IN contributes to proper packaging of the viral RNA 
genome (vRNA) within the viral capsid and examines the fate of improperly formed viral particles in target 
cells. 
IN is proposed to mediate proper placement of the vRNA within the capsid in mature virions by 
binding to vRNA at a defined binding site in its C-terminal domain. Mutations at the CTD RNA-binding 
site lead to the generation of morphologically aberrant virions with vRNA mislocalized outside of the empty 
capsid lattice, suggesting that IN-RNA binding is necessary for proper virion maturation. However, 
multiple IN mutations outside of the RNA-binding site cause the same morphological defects in virions, 
suggesting that another property of IN, such as its multimerization, may be responsible for its role in virion 
morphogenesis. In Chapter 2 we dissect the contribution of IN-RNA binding and IN multimerization to 
virion morphogenesis and demonstrate that IN-RNA binding accounts for the role of IN in virion 
maturation, although IN tetramerization is likely a prerequisite for RNA binding to occur. We further 
identify three separate mechanisms by which IN-RNA interaction can be inhibited, all of which prevent 
 viii 
proper virion maturation. In Chapter 3, we provide evidence that the morphological defects caused by IN 
mutations lead to the premature loss of the exposed vRNA and IN itself in infected target cells, preventing 
further viral replication.  
As a whole, this dissertation provides mechanistic insight into how IN contributes to virion 
morphogenesis by establishing IN-RNA binding as the determining factor by which IN ensures proper 
placement of the vRNA in viral particles, while highlighting the importance of proper IN multimerization 
for RNA-binding. This work also provides an explanation for the common block in viral replication 























































Human immunodeficiency virus type 1 (HIV-1) is the causative agent of AIDS, and since its discovery in 
19831,2 has become one of the leading causes of the death worldwide due to infectious disease. Intensive 
study of the HIV-1 life cycle has led to the identification of a handful of viral enzymes required for virus 
replication, and antiretroviral compounds that specifically inhibit the functions of these enzymes have 
transformed HIV-1 infection from a death sentence into a manageable disease. The HIV-1 integrase 
enzyme (IN) plays a vital role in the viral life cycle by catalyzing the integration of viral DNA into the 
host chromosome. This function has been successfully targeted by a class of antiretrovirals known as 
integrase strand-transfer inhibitors (INSTIs)3,4. Four FDA-approved INSTIs –raltegravir5, elvitegravir6, 
dolutegravir7, and bictegravir8- have become key components of anti-retroviral therapy regimens and are 
both highly effective and well tolerated4,9-11. A fifth –cabotegravir12- is currently in late stage clinical 
trials. However, despite high barriers with the second-generation INSTIs, treatment does select for drug 
resistance13-15 and mutations conferring resistance to multiple INSTIs have been reported in clinical 
settings16,17, highlighting the need for continued research and development of both improved and novel 
antiretroviral compounds. 
 It was recently discovered that IN has a second essential role in the HIV-1 life cycle during virion 
morphogenesis. IN binds the viral RNA (vRNA) genome in virions and is necessary for the proper 
placement of vRNA within the viral capsid lattice during virion maturation18. Loss of IN-RNA binding 
leads to mislocalization of the viral genome in virions and prevents viral replication in target cells18. This 
discovery opens up new avenues for therapeutic targeting of the second function of IN that is independent 
of its already targeted catalytic function. Here, I briefly review the HIV-1 life cycle, and then detail the 
roles IN plays in both integration and virion morphogenesis. A better mechanistic understanding of how 






1.2 Overview of the HIV-1 life cycle  
The HIV-1 life cycle can be broadly divided into an early stage (up to integration) and a late stage (after 
integration). Mature HIV-1 virions consist of two copies of single-stranded RNA genome and replicative 
enzymes (reverse transcriptase (RT) and IN) encased in a conical protein lattice made up by the viral 
capsid (CA) protein, together forming the viral core.  The viral genome inside the core exists in the form 
of a viral ribonucleoprotein complex (vRNP) bound and condensed by the viral nucleocapsid (NC) 
protein, and associated with RT and IN enzymes19. The viral core itself is enclosed within the viral lipid 
envelope derived from host cell plasma membrane. During budding the virion acquires the envelope 
(Env) glycoprotein trimers at its surface, which serve as receptors to mediate viral entry20. During entry 
Env engages the CD4 receptor and CXCR4/CCR5 coreceptors on the surface of the target cell, which are 
present predominantly on CD4+ T cells and cells of the monocyte/macrophage lineage21,22. Receptor 
binding induces a series of conformational changes in Env, resulting in membrane fusion and release of 
the viral core into the cytoplasm21,22. 
After entry, the viral core is transported towards the nucleus along microtubules23,24 and reverse 
transcription ensues. The viral reverse transcriptase enzyme (RT) binds the single-stranded viral RNA and 
uses it as a template to produce the linear double-stranded viral DNA (vDNA)25,26. During this stage, the 
core undergoes an uncoating process in which the capsid dissembles and CA monomers are shed from the 
lattice27. While uncoating and reverse transcription have long been thought to occur in the cytoplasm, 
recent studies have provided evidence that these processes are not completed until after nuclear entry28,29. 
IN remains associated with the reverse transcription complex and following completion of vDNA 
synthesis, a multimer of IN binds to both ends of the linear viral DNA to form the intasome, or the stable 
synaptic complex. The intasome complex is then transported into the nucleus, where IN catalyzes the 
integration of the viral DNA into the host cell chromosome30. 
 After the viral DNA is integrated into the host chromosome it serves as a template from which 
single full-length viral mRNAs are transcribed by the host RNA Polymerase II machinery31. This viral 
transcript can remain unspliced or undergo a complex series of splicing events, creating over 50 splice 
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variants of two size classes (1.8 kb and 4 kb)31. The fully spliced 1.8 kb class of HIV-1 mRNAs code for 
the regulatory Tat, Rev, and Nef proteins and are exported from the nucleus via the NXF1/NXT1 pathway 
32-34. The partially spliced 4 kb class of mRNAs code for the viral envelope Env and accessory proteins 
Vif, Vpr, and Vpu, while the unspliced full-length HIV-1 mRNAs can be packaged into virions as the 
genomic RNA or translated to generate the major structural proteins, Gag, and the Gag-Pol polyprotein32-
34. Translation of Gag-Pol, which additionally codes for the replicative enzymes protease (PR), RT, and 
IN, depends on programmed ribosomal frameshifting of the Gag ORF 35,36. Both partially spliced and 
unspliced HIV-1 RNAs are retained in the nucleus until they can be exported in a Rev-dependent 
fashion37,38. Once translated in the cytoplasm, the Rev protein is shuttled back into the nucleus where it 
binds the Rev response element (RRE) present in HIV-1 partially spliced and unspliced transcripts, and 
exports them from the nucleus through a CRM1-dependent pathway39-41.  
 Unspliced dimeric vRNA is trafficked to the plasma membrane by Gag and this complex 
subsequently nucleates the assembly of nascent virions42-44. During this process, the Gag and Gag-Pol 
polyproteins polymerize around the vRNA, acquire Env glycoproteins recruited to the budding site and 
virions bud off from the infected cell in an immature state. During or shortly after budding the virion 
undergoes a maturation process, in which the Gag and Gag-Pol polyproteins are cleaved into separate 
mature proteins by the virally encoded PR enzyme. This triggers a structural rearrangement within the 
virion, whereby the cleaved NC proteins condense the vRNA together with RT and IN to form the viral 
ribonucleoprotein complex (vRNP), the viral CA lattice assembles around the vRNP, and the now mature 




Figure 1: Overview of the HIV-1 life cycle 
HIV-1 virions contain two copies of a single-stranded RNA (vRNA, in gray) genome enclosed inside a 
conical capsid lattice or core. After viral entry the viral core is transported towards the nucleus and the 
vRNA is reversed transcribed into double-stranded DNA (vDNA, in red.) In the nucleus the vDNA is 
integrated into the host DNA and serves a template from which more vRNA is transcribed. vRNA and 
viral protein assemble at the plasma membrane and bud of from the cell as immature virions. During 






1.3 Integrase in integration 
A defining feature of the retroviral life cycle is integration of the reverse-transcribed viral DNA into the 
host chromosome. During integration, a multimer of IN binds either end of the linear viral DNA to form 
the intasome complex, which inserts the reverse-transcribed vDNA into the host DNA30,45. This function 
of IN was identified shortly after the discovery of HIV-1 in the early 1980s46-49, and has been extensively 
studied. Each IN molecule is composed of three functionally distinct domains: a N-terminal domain 
(NTD), a catalytic core domain (CCD), and a C-terminal domain (CTD). The NTD and CTD domains 
mediate DNA binding and play important structural roles in the intasome complex, while the CCD 
contains a highly conserved D,D,-35-E motif in the enzyme active site necessary for catalytic activity30,45. 
Mutations at these conserved residues, collectively referred to as class I IN mutations50-52, predictably 
abolish the catalytic activity of IN in vitro50 and block the viral life cycle at the integration stage in 
infected cells52.  
 IN is a dynamic protein, and can form a population of monomers, dimers, and tetramers in vitro, 
and as noted above forms multimers during integration53. Early studies indicated that IN may function as 
a multimer by demonstrating that catalytically inactive mutant IN proteins bearing substitutions at 
different sites could trans-complement each other and regain catalytic activity in vitro54-56. More recently, 
a mechanistic study using a small molecule inhibitor found that the compound binds at the interface 
between two dimers within an IN tetramer, and interferes with the exchange of IN subunits in a manner 
that correlates with its ability to inhibit IN catalytic activity, providing further evidence that proper IN 
multimerization is critical for its function57. 
The first retroviral intasome to be structurally characterized was that of the prototype foamy virus 
(PFV) from the spumavirus genus, which consists of a tetramer of IN made up of a dimer of dimers with 
viral DNA between the two subunits (Fig. 2)58-60. Each dimer includes an inner and outer IN molecule, 
with the inner subunits interacting with the viral and host DNA. The catalytic site in the inner IN CCD 
cooperatively coordinates the integration reaction with the NTD of the opposing inner IN, while the inner 
 
 7 
CTDs bind the host DNA and help hold the two dimers together. Meanwhile, the outer IN subunits further 
stabilize the complex by contacting the inner IN molecules at the CCD-CCD interface. 
It was generally assumed that the HIV-1 intasome complex shared a similar structure. Tetrameric 
IN binds to viral DNA in cross-linking experiments61, is catalytically active in vitro62, and has been 
observed to interact with viral DNA by atomic force microscopy63,64. However, recent studies have 
suggested that HIV-1 IN forms even higher-order multimers within the intasome complex65. While 
detailed structural analysis of the HIV-1 intasome has long been hindered by the propensity of HIV-1 IN 
to aggregate in solution, the aforementioned study overcame this issue by generating a hyper-active HIV-
1 IN mutant protein with improved solubility. Single particle cryo-EM structures of the HIV-1 IN 
construct in complex with DNA indicate that while the basic architecture of the IN tetramer is conserved 
across PFV and HIV-1, in HIV-1 a higher order multimer of several tetramers may be needed to 
efficiently integrate viral DNA, although a lower-order intasome consisting of an IN tetramer was also 




Figure 2: Structures of retroviral intasomes 
(A) Structure of the PFV IN intasome complex (pdb code 3os0.) Two IN dimers (green or blue) form a 
tetramer in complex with viral and host DNA (orange.) The inner monomers (darker shade) interact with 
DNA while the outer monomers (lighter shade) stabilize the complex. (B) Structure of the HIV-1 IN 
intasome complex (pdb code 5u1c.) The structure of the IN tetramer is similar to that of other 
retroviruses. 
 
After forming the intasome complex, IN catalyzes insertion of the viral DNA into the host DNA 
in two separate steps: 3’ processing and strand transfer (Fig. 3). During 3’ processing IN hydrolyzes a 
phosphodiester bond at either end of the viral DNA and removes two to three nucleotides in front of an 




























reaction, the intasome binds the target host DNA and uses the 3’ hydroxyls at either end of the viral DNA 
as nucleophiles to cut the host DNA in a staggered fashion, at the same time joining the viral DNA to the 
5’ ends of the cut host DNA69-71. Finally, the intasome dissembles, leaving loose 5’ overhangs on the viral 
DNA and a pair of single-stranded gaps on either side of the integrated viral DNA which are subsequently 
repaired by host cell machinery72. As a result of integration and subsequent gap repair a short segment of 
the target DNA sequence is duplicated, and flanks the integrated provirus. The length of the duplicated 




Figure 3: Mechanism of retroviral integration 
IN catalyzes integration in two steps: 3’ 
processing and strand transfer. During 3’ 
processing IN removes a dinucleotide from the 
3’ ends of the viral DNA (red) to expose free 3’ 
hydroxyls. During strand transfer IN inserts the 
3’ ends of the viral DNA into the host DNA 
(gray), leaving gaps in the target DNA and the 
loose 5’ ends of viral DNA. The gaps and loose 










HIV-1 does not integrate randomly but rather preferentially targets transcriptionally active genes 
in the nuclear periphery75-77. The pre-integration complex (PIC) is guided to its integration site by the 
chromatin-associated cellular protein lens epithelium-derived growth factor (LEDGF), also called 

































The LEDGF/p75 N-terminus consists of a PWWP domain, which binds nucleosomes trimethylated at 
Lys36 of histone 3 (H3K36me3), an epigenetic mark associated with transcriptionally active sites82,83. 
Stringent knockdown or knockout of LEDGF/p75 significantly diminishes HIV-1 titers by specifically 
inhibiting integration, and also changes integration site-selection84-86. Additionally, replacing the PWWP 
domain of LEDGF/p75 with a heterologous chromatin binding domain redirects HIV-1 integration to 
chromatin regions bound by the alternative domain87, further supporting the conclusion that LEDGF/p75 
is responsible for guiding and tethering the HIV-1 PIC to its integration site. 
Integrase strand-transfer inhibitors (INSTIs) prevent the integration reaction by targeting the 
strand transfer step3. These drugs bind to the active site of the IN CCD, displacing the reactive 3’ end of 
the viral DNA and preventing its insertion into the host DNA59. Mutations in the IN active site can confer 
resistance to INSTIs by directly or indirectly inhibiting drug binding, albeit at a viral fitness cost15,88,89. As 
a result, other compensatory mutations which increase the catalytic activity of IN are additionally found 
in patients undergoing INSTI therapy88,89. Emergence of resistance and cross-resistance is commonly 
observed for the two first-generation INSTIs, raltegravir and elvitegravir90. In spite of the improved 
potency and higher barriers for resistance, second-generation inhibitors also do select for viral 













1.4 Virion morphogenesis 
Virion assembly, release, and maturation is a multistep process involving coordinated protein-protein, 
RNA-RNA, and protein-RNA interactions92. Like all retroviruses, HIV-1 selectively packages two copies 
of full-length vRNA genome93, which are non-covalently dimerized at their 5’ untranslated region (5’ 
UTR). The HIV-1 5’ UTR is highly structured and forms six stem-loops with various roles in 
transcriptional regulation, reverse transcription, dimerization, RNA splicing, and packaging (Fig. 4)94. 
The regions responsible for RNA dimerization and packaging overlap, and contains four stem loop 
structures- SL1, SL2, SL3, and SL4, which are often collectively referred to as the packaging sequence, 
or psi (y). Dimerization of the RNA molecules is required for packaging and infectivity, and is initiated 
by a region termed the dimer initiation site in SL1. This site contains an apical bulge of nine bases, six of 
which form a palindrome, allowing the formation of classic Watson-Crick base pairs with the 
complementary sequence on the other RNA molecule, resulting in a “kissing-loop” structure42,94-96. The 
dimer initiation site is able to mediate dimerization of RNA molecules both in vitro97-100 and in vivo101-103, 




Figure 4: Structure of the HIV-1 RNA 5’ UTR 
The HIV-1 RNA 5’ UTR is highly structured and contains six stem loop structures, including SL1 (dimer 
initiation site or DIS), SL2 (splice donor site or SD), SL3, and SL4, which are collectively referred to as 







































































































































































































































































































































Early biochemical studies have found that the viral Gag polyprotein first interacts with vRNA in 
the cytoplasm as a monomer or low-order multimers, and brings the genome to the plasma membrane104. 
Further Gag molecules are then recruited to the nucleation site and Gag forms high-order multimers 
through interactions mediated by CA-CA interactions with neighboring Gag molecules. Many of these 
findings were later corroborated by total internal reflection fluorescence (TIRF) microscopy studies105-107. 
In these experiments, vRNA was observed reaching the plasma membrane first, followed by recruitment 
of further Gag molecules soon after. In the absence of Gag, vRNA moved rapidly towards and away the 
plasma membrane, suggesting that Gag is responsible for docking vRNA at the plasma membrane. Over 
time the amount of Gag at the nucleation site increased, consistent with many Gag molecules 
polymerizing around the initial Gag-RNA complexes 105-107.  
The main contact point with vRNA within Gag is its NC domain, which is later cleaved to form 
mature NC protein during virion maturation. The RNA 5’ UTR SL2 and SL3 structures appear to be 
recognized by NC, which adopts distinct conformations to bind either stem loop 108,109. In addition to 
recognizing structured elements on the HIV-1 RNA, there is also evidence that Gag recognizes dimerized 
RNA110. While a minimal sequence both necessary and sufficient for the packaging of the HIV-1 genome 
has not been defined, a RNA sequence containing SL1, SL2, and SL3 can both dimerize and bind NC in 
vitro111, and mutations within the 5’ packaging sequence prevent RNA being packaged into viral 
particles112. Likewise, deletion of NC prevents RNA from being packaged and generates particles devoid 
of the HIV-1 genome 113. NC binding to RNA is mediated by two CCHC-type zinc knuckle motifs 114-116, 
and swapping the NC domain of HIV-1 Gag with that of murine leukemia virus (MLV) Gag allows the 
chimeric HIV-1 Gag protein to package the MLV genome117,118, further demonstrating the importance of 
NC in genome packaging. Interestingly, replacing the HIV-1 Gag NC domain with the mouse mammary 
tumor virus (MMTV) NC domain does not change Gag’s preference for packaging HIV-1 RNA119, 
suggesting that NC alone does not account for the specificity of HIV-1 genome packaging. Gag-RNA 
binding is dynamic, and changes as virions assemble, bud, and mature. In the cytosol the Gag NC domain 
preferentially binds structured elements of the HIV-1 genome and displays a preference for G- and U-rich 
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elements on cellular mRNAs, while the matrix domain (MA) selectively binds cellular tRNAs120. In 
contrast, during virion assembly at the plasma membrane NC preferentially binds A-rich sequences on the 
viral genome as well as on cellular mRNAs, while MA dissociates from tRNAs and binds the plasma 
membrane, facilitating budding of the virion120.  
After assembling at the plasma membrane spherical immature virions bud off from the infected 
cell (Fig. 5). In immature particles approximately 2000-4000 Gag molecules121 are radially arranged 
along the inside of the viral envelope, with MA anchored to the membrane at one end and NC, still bound 
to vRNA, projecting towards the interior. Immediately after or during budding, the virion undergoes a 
maturation process in which the viral protease enzyme (PR) cleaves Gag and Gag-Pol at multiple sites in 
a defined sequence to produce independent viral structural and replicative proteins. Gag is cleaved to 
produce MA, CA, NC, p6, and two spacer peptides (SP1 and SP2) while Pol is cleaved to yield the viral 
enzymes, PR, RT, and IN42,43,122. The processed proteins then rearrange to form the structure of the mature 
virion. MA remains associated with the inner side of the viral membrane and forms a discontinuous shell 
immediately under the membrane. Approximately 1000-1500 monomers of CA assemble to form the 
capsid lattice121. In HIV-1 the capsid takes on a characteristic conical shape, and is composed of 
approximately 250 hexameric and 12 pentameric rings of CA that are stabilized by interactions within and 
between subunits123-128. Enclosed inside the viral capsid are the two single-stranded HIV-1 RNA 




Figure 5: Virion morphogenesis and maturation 
(A) The Gag and Gag-Pol polyproteins assemble with vRNA at the plasma membrane, bud from the 
surface of the cell as immature virions, and then undergo a maturation process. (B) During maturation PR 
cleaves Gag and Gag-Pol into independent structural and replicative proteins. 
 
 Thus, virion morphogenesis is a highly complex process that requires coordinated interaction 
between the Gag polyprotein and viral RNA, as well as regulated cleavage of Gag into separate mature 
proteins. While the process has long been thought to be driven solely by Gag, there is emerging evidence 



































1.5 Integrase in virion maturation 
While integration is the canonical function of IN, early mutagenesis studies indicated that IN may 
also play other roles in virus replication. In particular, a group of IN substitutions referred to as class II IN 
mutations, lead to pleiotropic effects in HIV-1 replication, including defects in particle assembly52,129-141, 
morphogenesis18,52,131,137-139,142,143 and reverse transcription in target cells18,51,52,133,135-137,139,141-159, in some 
cases without impacting IN catalytic function in vitro50,131,132,135,136,145,146,149,151,160,161. When visualized 
using electron microscopy, viral particles of class II IN mutant viruses contain vRNP complexes 
mislocalized outside the capsid lattice 18,52,131,137-139,142,143. A similar phenotype was noted in IN-deleted 
viruses138, again suggesting that IN is necessary for proper virion morphogenesis. Such aberrant viral 
particles are generally referred to as “eccentric particles,” due to the mislocalization of the vRNPs outside 
the capsid lattice, and are morphologically distinct from immature virions (Fig. 6).  
 
Figure 6: Virion morphologies 
Immature viral particles consist of many molecules of Gag and Gag-Pol concentrically arranged along the 
inner leaflet of the viral membrane and bound to vRNA at the NC domain. In mature viral particles the 
vRNA is bound by NC and condensed with RT and IN to form the vRNP, which is enclosed in the conical 
capsid lattice made up of CA monomers. In eccentric viral particles the vRNP is mislocalized outside of 
the capsid. 
 
Surprisingly, it was recently discovered that treatment of virus producing cells with a class of 2-
(quinolin-3-yl) acetic acid derivatives known as allosteric IN inhibitors (ALLINIs) (also called 
noncatalytic IN inhibitors (NCINIs), lens epithelium-derived growth factor (LEDGF)/p75-IN inhibitors 
(LEDGINs), IN-LEDGF/p75 allosteric inhibitors (INLAIs), or multimeric IN inhibitors (MINIs)) results 





















prevent integration by interfering with IN binding to the cellular cofactor, lens epithelium–derived growth 
factor (LEDGF/p75), important for targeting the viral preintegration complex to the host chromosome164. 
The compounds compete with LEDGF binding to IN by engaging the V-shaped binding pocket created by 
the catalytic core domain of two IN dimers in the intasome complex143,164-169. In addition to preventing IN-
LEDGF interaction, ALLINIs also prevent integration in a LEDGF-independent manner by inducing 
aberrant IN multimerization, locking IN in catalytically inactive multimers which are unable to assemble 
on viral DNA and carry out the integration reaction165,169. However, subsequent studies found that many 
ALLINIs are more potent when added to producer cells, and inhibit viral replication at the later stages of 
the viral life cycle143,162,163,166-168. Specifically, treatment with ALLINIs interferes with virion 
morphogenesis and leads to the generation of eccentric viral particles with vRNPs mislocalized outside 
the capsid lattice, strikingly similar to those generated by class II IN mutations143,162,163,167. Similar to the 
mechanism by which they can prevent integration, ALLINIs are proposed to interfere with virion 
morphogenesis by inducing aberrant IN multimerization, and mutations that confer resistance to ALLINIs 
also prevent ALLINI-induced IN multimerization162,170. Many class II IN mutations also alter IN 
multimerization62,160,171,172, suggesting that proper multimerization is important for IN’s function during 
virion morphogenesis. However, a defined mechanism by which IN ensures viral RNA is correctly 
packaged inside the capsid lattice remained elusive for many years. 
A seminal study in 2016 revealed that IN binds viral genomic RNA in mature virions, and that 
IN-RNA binding is necessary for viral replication18. Crosslinking immunoprecipitation sequencing 
(CLIP-seq), an approach that captures protein-RNA interactions in relevant physiological settings120, was 
instrumental in this discovery and demonstrated that IN binds the HIV-1 genome at discrete sites with a 
distinct binding pattern from that of NC. IN not only binds RNA, but also modulates RNA structure in 
vitro by bridging multiple RNA molecules together18. Several basic residues in the IN CTD- K264, K266, 
and K273- directly interact with RNA, and substitutions at these positions abolish IN-RNA binding in 
virions. Importantly, virus production in the presence of ALLINIs, BI-D and BI-B2, also prevented IN-
RNA binding, likely through aberrant IN multimerization as detailed below18. Finally, inhibiting IN 
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interaction with RNA, either by introducing mutations at the CTD binding site or by ALLINI-treatment, 
leads to the generation of eccentric, non-infectious viral particles with vRNPs mislocalized outside of the 
core18. 
 
1.6 Concluding remarks 
HIV-1 IN is a multifunctional protein with an essential role in at least two stages of the viral life cycle. 
During integration, IN binds both viral and host DNA and orchestrates the insertion of the viral DNA into 
the host chromosome, fulfilling a critical step in retroviral replication. During virion morphogenesis, IN 
binds viral RNA and ensures its proper placement within the capsid. Both integration and virion 
morphogenesis are essential for virus replication, and inhibiting the role of IN in either of these processes 
is an attractive therapeutic strategy. IN’s catalytic function in integration has already been successfully 
targeted by a number of antiretroviral drugs, but viral mutations that confer resistance to these compounds 
have been reported in clinical settings. Importantly, because all clinically approved IN inhibitors target 
the same function of IN, the emergence of resistance mutations can often preclude the use of multiple 
drugs. Therefore, compounds that target the novel role of IN in virion maturation could be valuable 
additions to the current antiretroviral arsenal. The discovery that IN-RNA binding is critical to proper 
placement of viral RNA in virions offers a glimpse into the role IN plays in the late stage of the viral life 
cycle, but much is still unknown about how IN functions in virion morphogenesis. A better understanding 
of this function of IN will illuminate an important step in the life cycle of HIV-1, and perhaps other 
retroviruses, and can inform the development of both new and improved drugs for the treatment of HIV. 
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A large number of human immunodeficiency virus 1 (HIV-1) integrase (IN) alterations, referred to as class 
II substitutions, exhibit pleotropic effects during virus replication. However, the underlying mechanism for 
the class II phenotype is not known. Here we demonstrate that all tested class II IN substitutions 
compromised IN-RNA binding in virions by one of three distinct mechanisms: i) markedly reducing IN 
levels thus precluding formation of IN complexes with viral RNA; ii) adversely affecting functional IN 
multimerization and consequently impairing IN binding to viral RNA; iii) directly compromising IN-RNA 
interactions without substantially affecting IN levels or functional IN multimerization. Inhibition of IN-
RNA interactions resulted in mislocalization of the viral ribonucleoprotein complexes outside the capsid 
lattice, which led to premature degradation of the viral genome and IN in target cells. Collectively, our 
studies uncover causal mechanisms for the class II phenotype and highlight an essential role of IN-RNA 















Infectious HIV-1 virions are formed in a multistep process coordinated by interactions between the HIV-1 
Gag and Gag-Pol polyproteins, and the viral RNA (vRNA) genome. At the plasma membrane of an infected 
cell, Gag and Gag-Pol molecules assemble around a vRNA dimer and bud from the cell as a spherical 
immature virion, in which the Gag proteins are radially arranged1-3. As the immature virion buds, the viral 
protease enzyme is activated and cleaves Gag and Gag-Pol into their constituent domains, triggering virion 
maturation1,2. During maturation the cleaved nucleocapsid (NC) domain of Gag condenses with the RNA 
genome and pol-encoded viral enzymes [reverse transcriptase (RT) and integrase (IN)] inside the conical 
capsid lattice, composed of the cleaved capsid (CA) protein, which together form the core1-3.  
After infection of a target cell, RT in the confines of the reverse transcription complex (RTC) 
synthesizes linear double stranded DNA from vRNA4. The vDNA is subsequently imported into the 
nucleus, where the IN enzyme catalyzes its insertion into the host cell chromosome5,6. Integration is 
mediated by the intasome nucleoprotein complex that consists of a multimer of IN engaging both ends of 
linear vDNA7. While the number of IN protomers required for intasome function varies across Retroviridae, 
single particle cryogenic electron microscopy (cryo-EM) structures of HIV-1 and Maedi-visna virus 
indicate that lentivirus integration proceeds via respective higher-order dodecamer and hexadecamer IN 
arrangements8,9, though a lower-order intasome comprised of an HIV-1 IN tetramer was also resolvable by 
cryo-EM9.  
A number of IN substitutions which specifically arrest HIV-1 replication at the integration step 
have been described10. These substitutions are grouped into class I to delineate them from a variety of other 
IN substitutions, which exhibit pleiotropic effects and are collectively referred to as class II substitutions10-
12. Class II IN substitutions or deletion of entire IN impair proper particle assembly11,13-25, morphogenesis 
11,15,21-23,26-28 and reverse transcription in target cells10,11,17,19-21,23,25-44, in some cases without impacting IN 
catalytic function in vitro15,16,19,20,30,31,34,36,45-47. A hallmark morphological defect of these viruses is the 
formation of aberrant viral particles with viral ribonucleoprotein (vRNP) complexes mislocalized outside 
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of the conical CA lattice11,15,21-23,26-28. Strikingly similar morphological defects are observed in virions 
produced from cells treated with allosteric integrase inhibitors (ALLINIs, also known as LEDGINs, 
NCINIs, INLAIs or MINIs)26,27,48-55. ALLINIs induce aberrant IN multimerization in virions by engaging 
the V-shaped pocket at the IN dimer interface, which also provides a principal binding site for the host 
integration targeting cofactor lens epithelium-derived growth factor (LEDGF)/p7550,54,56-60. The recent 
discovery that HIV-1 IN binds to the vRNA genome in virions and that inhibiting IN-RNA interactions 
leads to the formation of eccentric particles provided initial clues about the role of IN during virion 
morphogenesis28. 
HIV-1 IN consists of three independently folded protein domains: the N-terminal domain (NTD), 
catalytic core domain (CCD), and C-terminal domain (CTD)7,61, and vRNA binding is mediated by a 
constellation of basic residues within the CTD28. However, class II IN substitutions are located throughout 
the entire length of the IN protein10,12, which raises the question as to how these substitutions impair virus 
maturation. The structural basis for IN binding to RNA is not yet known; however, in vitro evidence 
indicates that IN binds RNA as lower-order multimers, and conversely RNA binding may prevent the 
formation of higher order IN multimers28. Notably, aberrant IN multimerization underlies the inhibition of 
IN-RNA interactions by ALLINIs28 and subsequent defects in virion maturation26-28,48,49,51-55. Therefore, it 
seems plausible that class II IN substitutions may exert their effect on virus replication by adversely 
affecting functional IN multimerization. However, a systematical evaluation of the effects of IN 
substitutions on IN multimerization, IN-RNA binding, and virion morphology is lacking. As such, it 
remains an open question how functional IN multimerization and/or IN-RNA interactions influence correct 
virion morphogenesis. 
 In this work, we aimed to determine the molecular basis of how class II IN substitutions exert their 
effects on HIV-1 replication. In particular, by detailed characterization of how class II substitutions impact 
IN multimerization, IN-RNA interactions and virion morphology, we aimed to dissect whether loss of IN 
binding to vRNA or aberrant IN multimerization underlies the pleiotropic defects observed in viruses 
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bearing class II IN mutations. Remarkably, we found that class II substitutions either prevented IN binding 
to the vRNA genome or precluded the formation of IN-vRNA complexes through reducing or eliminating 
IN from virions. We show that IN tetramers have a strikingly higher affinity towards vRNA than IN 
monomers or dimers, and a large number of class II IN substitutions inhibited IN binding to RNA indirectly 
through modulating functional IN tetramerization. In contrast, R262A/R263A and R269A/K273A 
substitutions within the CTD and the K34A change within the NTD did not perturb IN tetramer formation, 
and thus likely directly interfered with IN binding to RNA. Irrespective of how IN-RNA binding was 
inhibited, all class II IN mutant viruses formed eccentric particles with vRNPs mislocalized outside of the 
CA lattice. Our findings uncover causal mechanisms for the class II phenotype and highlight the essential 




Class II IN substitutions cluster at interfaces that mediate IN multimerization  
Substitutions in IN that exhibited a class II phenotype (i.e. assembly, maturation or reverse transcription 
defects10-44,62,63 or affected IN multimerization46,64-67 were selected from past literature (Table 1). Although 
a structure of IN bound to RNA is not currently available, the location of these substitutions depicted on 
the model of a tetrameric IN complex (based on cryo-EM structure of the HIV-1 intasome complex 
consisting of IN and DNA9) suggest that the targeted amino acids are positioned at or near monomer-
monomer or dimer-dimer interfaces (Figure 1A-B). While not apparent in the tetrameric intasome complex, 
the CTD mediates IN tetramer-tetramer interactions in the higher-order dodecamer IN structure9 and has 




Figure 1. Class II IN substitutions locate throughout IN and cluster at interfaces that mediate IN 
multimerization. (A) Location of class II IN substitutions used in this study displayed in red on a single 
IN monomer within the context of the HIV-1 IN tetramer intasome structure consisting of a dimer of 
dimers (PDB 5U1C). The two dimers are displayed in either gray or green, with individual monomers 
within each displayed in different shades. The DNA is omitted for clarity. (B) View of the structure 













































































Table 1. Class II IN substitutions used in this study 
Substitution Domain Remarks 
H12N NTD 
 
• Eccentric virion morphology11 
• IN levels reduced in virions11 
• Multimerization defect in vitro65 
• Defective for reverse transcription19 
K14A • Multimerization defect in vitro68 
N18I • IN levels undetectable in virions69 
K34A • Defective for reverse transcription19 
• Catalytically active in vivo19 
E87A CCD 
 
• Multimerization defect in vitro66 
E96A • Multimerization defect in vitro66 
Y99A • Multimerization defect in vitro66 
K103E • IN levels reduced in virions69 
W108R • IN levels reduced in virions69 
V165A • Eccentric virion morphology27 
• Defective for reverse transcription20,32 
• Catalytically active in vivo 19,20,70 
F185K • Eccentric virion morphology15 
• Multimerization defect in vitro71 
• Catalytically active in vitro15  
K186A • Multimerization defect in vitro68 
K186E • Catalytic defect in vitro65 
• Multimerization defect in vitro65 
R187A • Multimerization defect in vitro68 
K188E • Multimerization defect in vitro72 
R199A • Catalytically active in vivo73 
Q214L/Q216L CTD • Defective for reverse transcription20 
• Catalytically active in vitro20 
K215A/K219A • Defective for reverse transcription20 
• Catalytically active in vitro 20 
R228A • Defective for reverse transcription19 
K236E • Defective for reverse transcription19 
L241A • Multimerization defect in vitro46 
• Catalytic defect in vitro46 
L242A • Multimerization defect in vitro 46 
• Catalytic defect in vitro46 
K258A • Defective for reverse transcription19 
V260E • Misfolded protein46 
• Catalytic defect in vitro46 
R262A/R263A • Defective for reverse transcription19 
R269A/K273A • Defective for RNA-binding74 
• Eccentric virion morphology74 





Characterization of the replication defects of class II IN mutant viruses 
IN mutations were introduced into the replication competent pNL4-3 molecular clone and HEK293T cells 
were transfected with the resulting plasmids. Cell lysates and cell-free virions were subsequently analyzed 
for Gag/Gag-Pol expression, processing, particle release and infectivity. While substitutions in IN had no 
measurable effect on Gag (Pr55) expression, modest effects on Gag processing in cells was visible for 
several missense mutant viruses including H12N, N18I, K34A, Y99A, K103E, W108R, F185K, 
Q214L/Q216L, L242A, V260E, as well as the DIN mutant (Figure 2). Nevertheless, particle release was 
largely similar between WT and IN mutant viruses, as evident by the similar levels of CA protein present 
in cell culture supernatants (Figure 2, lower panels).  
Three distinct phenotypes became apparent by assessing the amount of virion-associated IN and 
RT enzymes (Figure 2, Figure 2- Figure Supplement 1). First, virion-associated IN was at least 5-fold less 
than WT with several mutants, including H12N, N18I, K103E, W108R, F185K, L242A, and V260E (Figure 
2, Supplemental Table 1). Notably, these substitutions also reduced levels of Gag-Pol processing 
intermediates in producer cells (Figure 2) and RT in virions (Figure 2, Figure 2- Figure Supplement 1), 
suggesting that they likely destabilized the Gag-Pol precursor. Near complete lack of processing 
intermediates with the K14A and N18I substitutions, despite the presence of fully processed RT and IN in 
virions (detected using a separate polyclonal antibody), is likely due to inaccessibility of epitopes 
recognized by the monoclonal anti-IN antibody in the processing intermediates. Second, the R228A 
substitution abolished full-length IN in virions without impacting cell- or virion-associated Gag-Pol levels 
or processing intermediates; however, a faster migrating species generated by aberrant IN processing and/or 
IN degradation was visible. A similar but more modest defect was observed for the K34A mutant, which 
was incorporated into virions at a modestly reduced level alongside a smaller protein species. Third, the 




Figure 2. Characterization of the replication defects of class II IN mutant viruses. Immunoblot 
analysis of Gag and Gag-Pol products in cell lysates and virions. HEK293T cells were transfected with 
proviral HIV-1NL4-3 expression plasmids carrying pol mutations encoding for the indicated IN 
substitutions. Cell lysates and purified virions were harvested two days post transfection and analyzed by 
immunoblotting for CA, IN and, in the case of virions, RT. Representative image of one of four 
independent experiments is shown.  
 
Class II IN mutants abolish IN binding to RNA 
Using complementary in vitro and CLIP-based approaches, we have previously shown that viral genomic 
RNAs (vRNA) constitute the primary RNA species bound by IN in virions and that IN interacts with the 
viral genome through multiple basic residues (i.e. K264, K266, R269, K273) in its CTD28. In addition, IN-
RNA interactions could also depend on proper IN multimerization, as ALLINI-induced aberrant IN 
multimerization potently inhibited the ability of IN to bind RNA28. Based on this, in the next set of 
experiments, we aimed to determine whether class II IN mutants bind vRNA, and if not, whether improper 
IN multimerization may underlie this defect.  
IN-vRNA complexes were immunoprecipitated from UV-crosslinked virions and the levels of 

























































































































of IN in virions (Figure 2, Supplementary Table 1) were excluded from these experiments. All class II IN 
mutant viruses contained similar levels of vRNA, ruling out any inadvertent effects of the alterations on 
RNA packaging (Figure 3A). While the catalytically inactive IN D116N bound vRNA at a level that was 
comparable to the WT, nearly all of the class II IN mutant proteins failed to bind vRNA (Figure 3B). The 
E96A substitution, which had a fairly modest effect on virus titers as compared to other IN mutants (Chapter 
3, Figure 1A), decreased but did not abolish the ability of IN to bind RNA (Figure 3B). Thus, lack of RNA 
binding ability is a surprisingly common property of a disperse set of class II IN mutants, despite the fact 
that many of the altered amino acid residues are distally located from the CTD. 
 
Figure 3. Class II IN substitutions prevent IN binding to the vRNA genome in virions. (A) Analysis 
of the levels of packaged viral genomic RNA in WT and IN mutant HIV-1NL4-3 virions. vRNA extracted 
from purified virions was measured by Q-PCR. Data was normalized to account for differences in particle 
yield using an RT activity assay. Normalized quantities of vRNA are expressed relative to WT (set to 1). 
Columns show the average of three-four independent experiments (open circles) and error bars represent 
standard deviation (ns, not significant, by one-way ANOVA). (B) Representative autoradiogram of IN-
RNA adducts immunoprecipitated from WT or IN mutant HIV-1NL4-3 virions. The amount of 
immunoprecipitated material was normalized such that equivalent levels of WT and mutant IN proteins 
were loaded on the gel, as also evident in the immunoblots shown below. Levels of IN and CA in input 
virion lysates is shown in the lower immunoblots. Data is representative of three independent replicates. 
 
IN multimerization plays a key role in RNA binding 
As it seemed unlikely that all of the class II IN substitutions directly inhibited IN binding to RNA, we 























































































































































































































































































whether class II IN substitutions altered IN multimerization in a relevant setting, purified HIV-1NL4-3 virions 
were treated with ethylene glycol bis (succinimidyl succinate) (EGS) to covalently crosslink IN in situ and 
virus lysates were analyzed by immunoblotting. IN species that migrated at molecular weights consistent 
with those of monomers, dimers, trimers and tetramers were readily distinguished in WT virions (Figure 4-
Figure Supplement 1). In the majority of the class II mutant particles, IN appeared to exist as monomers as 
well as higher molecular weight species, representing IN multimers or IN aggregates, with little dimers and 
no readily detectable tetramers (Figure 4A, Figure 4-Figure Supplement 1). In contrast, K34A, E96A, 
R262A/R263A and R269A/K273A IN mutants formed dimers and tetramers at similar levels to the WT 
(Figure 4A, Figure 4-Figure Supplement 1). An undefined smear was present at higher molecular weights 
for all viruses, possibly as a result of the formation of large IN aggregates upon cross-linking (Figure 4-
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Figure 4. Multimerization properties of class II IN mutants in virions and in vitro. (A) Purified HIV-
1 virions were crosslinked with 1mM EGS and analyzed by immunoblotting as detailed in Materials and 
Methods. IN signal at the molecular weights of 32 kDa (monomers), 64 kDa (dimers), and 96 kDa 
(trimers) was measured and divided by the total signal of the three multimeric species for each virus. 
Columns show average of three independent experiments and error bars represent standard error of the 
mean (**P < 0.05 and *P < 0.01, by one-way ANOVA with Dunnett’s multiple comparison test).  (B) 
SEC profiles of 10 µM of WT and indicated IN mutants are shown. X-axis indicates elution volume (mL) 
and Y-axis indicate the intensity of absorbance (mAU). Tetramers (T), Dimers (D) and Monomers (M) 
are indicated. Representative chromatograms from two independent analyses are shown.  
 
To corroborate these findings, we analyzed the oligomeric states of recombinant WT, K34A, E96A, 
V165A, K188E, R199A, Q214L/Q216L, K236E, K258A and R262A/R263A IN proteins by SEC (Figure 
4B).  Oligomeric states of additional class II IN mutants have previously been characterized in 
vitro28,46,65,66,68,71,72 and are summarized in Supplementary Table 2. In line with the crosslinking studies in 
virions, WT, K34A and R262A/R263A INs formed tetramers, while the levels of dimers varied for different 
mutants. For example, while IN R262A/R263A presented similar levels of tetramers and dimers, IN K34A 
was primarily tetrameric with a minor dimeric species, as evident by the broad right shoulder of the 
tetrameric SEC peak (Figure 4B). In contrast, the majority of other IN mutants almost exclusively formed 
dimers and monomers with little evidence for tetramer formation (Figure 4B). While Q214L/Q216L and 
K236E IN were predominantly dimeric, the broad base of their chromatograms revealed some evidence for 
tetramers and monomers as well (Figure 4B).  
Next we tested the mutant INs for their ability to bind and bridge cognate RNA oligonucleotides in 
vitro. We have previously shown that recombinant IN binds TAR RNA with a high affinity and provides a 
nucleation point to bridge and condense RNA28. However, IN oligomeric states required for its ability to 
bind and bridge RNA molecules are not known. We separated WT monomeric, dimeric and tetrameric 
forms of WT IN by SEC and examined their binding to TAR RNA28. Remarkably, while WT IN tetramers 
bound to TAR RNA with high affinity (2.68 ± 0.16 nM), neither IN dimers nor monomers showed evidence 
of binding (Figure 5A). In line with this, we found that WT tetramers rather than dimers effectively bridged 
RNA oligonucleotides in vitro (Figure 5B).  
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  We then analyzed a set of class II IN mutants for their ability to bind and bridge TAR RNA in vitro 
(Figure 5C).  All class II IN mutants that predominantly formed dimers (Figure 4B) had reduced affinity 
for RNA compared to WT IN (Figure 5C, Figure 5-Figure Supplement 1B-D). Furthermore, these mutations 
had even more deleterious effects on the ability of IN to bridge the RNA molecules (Figure 5C). Although 
IN K34A and IN R262A/R263A could both form tetramers, IN K34A showed a reduced binding affinity 
for RNA while IN R262A/R263A did not bind RNA at all (Figure 5C, Figure 5-Figure Supplement 1A), 
suggesting that these residues may be directly involved in IN binding to RNA. Collectively, these results 
pointed to a key role of IN tetramerization for high affinity binding to RNA and more critically for RNA 
bridging. Thus, these findings suggest that a defect in proper multimerization underlies the inability of the 
majority of class II IN mutants to form functional complexes with vRNA.  
 
Figure 5. RNA-binding properties of class II IN mutants. (A) Analysis by AlphaScreen assay of 100 
nM WT IN monomers, dimers, and tetramers binding to biotinylated TAR RNA after separation by SEC. 
Graphed data is the average of three independent experiments and error bars indicate standard deviation. 
(B) Summary of WT IN dimers and tetramers bridging TAR RNA at different protein concentrations as 
measured by AlphaScreen assay. Graphed data is the average of four independent experiments and error 
bars indicate standard deviation. (C) Summary of mutant INs binding to TAR RNA (black bars) and 
bridging TAR RNA (gray bars) compared to WT IN. Percent binding was calculated for each mutant IN by 
comparing the calculated Kd value to that of WT IN (normalized to 100%) within an experiment. Percent 
bridging was calculated by comparing the Alpha Counts at 320 nM for each protein to that of WT 


























































































Class II IN substitutions generate virions with eccentric morphology 
We next sought to determine how preclusion or inhibition of IN-vRNA interactions correlated with particle 
morphology. Virion morphology of a subset of the IN mutants that inhibited vRNA interactions by three 
different mechanisms; i.e. those that decreased IN levels in virions (N18I and W108R), those that may have 
directly inhibited IN binding to RNA (K34A, R262A/R263A), and those that primarily altered IN 
multimerization (E87A, E96A, F185K, R187A, L241A, L242A), was assessed by transmission electron 
microscopy (TEM). As expected, the majority of WT particles contained an electron dense condensate 
representing vRNPs inside the CA lattice, whereas an DRT-IN deletion mutant virus produced similar levels 
of immature particles and eccentric particles (Figure 6A-B). Remarkably, irrespective of how IN-RNA 
interactions were inhibited, 70-80% of nearly all class II IN mutant particles exhibited an eccentric 
morphology (Figure 6A-B). Of note, the E96A mutant tended to produce less eccentric and more mature 
particles than the other IN mutants. Because IN E96A retained partial binding to vRNA in virions (Figure 
3B) and partial infectivity (Chapter 3, Figure 1A), we conclude that this infection-deferred mutant harbors 




Figure 6. Analysis of class II IN mutant virion morphologies viruses by TEM. (A) Representative 
TEM images of WT, K14A, N18I, K34A, E87A, E96A, W108R, F185K, R187A, L241A, L242A, 
R262A/R263A, and ∆RT-IN HIV-1NL4-3 virions. Magnification is 30,000x (scale bar, 100 nm). Black 
arrows indicate mature particles containing conical or round cores with associated electron density; 
triangles indicate eccentric particles with electron dense material situated between translucent cores and 
the viral membrane; diamonds indicate immature particles. (B) Quantification of virion morphologies. 
Columns show the average of two independent experiments (more than 100 particles counted per 
experiment) and error bars represent standard deviation (****P < 0.0001, by repeated measures one-way 
ANOVA.)  
 
 Next, we tested whether inhibition of IN-RNA interactions through class II substitutions changes 
the localization of IN in virions. The premise for this is based on our previous finding that disruption of IN 
binding to vRNA through the IN R269A/K273A substitution leads to separation of a fraction of IN from 
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dense vRNPs and CA containing complexes76. Thus, we predicted that inhibition of IN-RNA interactions 
through the above class II substitutions could lead to a similar outcome. To this end, WT or class II IN 
mutant virions stripped of the viral lipid envelope by brief detergent treatment were separated on sucrose 
gradients, and resulting fractions were analyzed for CA, IN, and matrix (MA) content by 
immunoblotting76,77. As before76, WT IN migrated primarily in dense fractions, whereas the R269A/K273A 
mutant migrated bimodally (Figure 7A, B). In contrast to our hypothesis, the majority of IN mutants 
sedimented similarly to WT IN and settled in the denser gradient fractions (Figure 7A, B). Exceptions were 
the K34A and R262A/R263A IN mutants, a fraction of which migrated in soluble fractions similar to the 
R269A/K273A mutant, suggesting their localization outside of the capsid lattice. None of the IN 
substitutions affected the migration pattern of CA (Figure 7C), which distributed bimodally between the 
soluble and dense fractions, nor the distribution of MA (data not shown), which was found in mainly the 
soluble fractions. These results suggested that, with the exception of the K34A, R262A/R263A, and 
R269A/K273A, IN mutant proteins may remain associated with the CA lattice despite inhibition of IN-
vRNA interactions. Alternatively, class II IN mutants may localize outside of the CA lattice but form 




Figure 7. Biochemical analysis of class II IN mutant virus particles. (A) Immunoblot analysis of 
sedimentation profiles of IN in WT or IN mutant virions. Purified HIV-1NLGP virions were analyzed by 
equilibrium density centrifugation as detailed in Materials and Methods. Ten fractions collected from the 
top of the gradients were analyzed by immunoblotting using antibodies against IN. Representative images 
from one of four independent experiments are shown. (B) Quantitation of IN signal intensity in 
immunoblots as in (A) are shown. Profile of WT virions is denoted in black, IN mutants that led to 
bimodal IN distribution are shown in red and others are shown in grey. Graphed data is the average of two 
independent experiments and error bars indicate the range. (C) Representative immunoblot analysis of 
sedimentation profile of CA in WT virions and quantitation of CA signal intensity in immunoblots are 
shown. Profile of WT virions is denoted in black, IN mutants that led to bimodal IN distribution are 
shown in red and others are shown in grey. Graphed data is the average of two independent experiments 
and error bars indicate the range. 
 
 To test these possibilities, we combined the CA destabilizing K203A substitution, which leads to 
premature disassembly of the CA lattice in vitro78, with class II IN substitutions K34A, E87A, and 
































































































R262A/R263A. Biochemical fractionation of these viruses following membrane stripping as above yielded 
a similar IN distribution primarily in dense fractions (Figure 7-Figure Supplement 1A). Note that the 
K203A CA mutation caused the loss of CA in the dense fractions compared to WT viruses, indicating that 
the CA lattice was indeed destabilized (Figure 7-Figure Supplement 1A). Thus, migration of IN in dense 
fractions over the gradients does not appear to be dependent on its being enclosed in an intact CA lattice. 
We then asked if the mutant IN molecules may settle in the dense fractions due to some residual RNA 
binding not detected by the CLIP assay (Figure 3B). To test this, we introduced the above class II IN 
substitutions into a Gag-chimeric virus (Gag-bZIP) in which the NC domain is replaced by the leucine 
zipper domain from the yeast GCN4 protein and as a result is devoid of RNA79,80. Of note, this modification 
additionally destabilized the CA lattice, as indicated by the lack of a second population of CA in dense 
fractions (Figure 7-Figure Supplement 1B). Lack of RNA packaging and an unstable CA lattice with the 
Gag-bZIP virus also did not affect the migration pattern of IN over the sucrose gradients (Figure 7-Figure 
Supplement 1B), nor did presence of RNAse throughout the fractionation experiment (data not shown). The 
results from these experiments indicate that migration of IN in dense sucrose gradients is independent of 
its being enclosed in an intact CA lattice and of its binding to vRNA. 
 
2.4 DISCUSSION 
Our findings highlight the critical role of IN-vRNA interactions in virion morphogenesis and provide the 
mechanistic basis for how diverse class II IN substitutions lead to similar morphological defects. We 
propose that class II IN substitutions lead to the formation of eccentric particles through three distinct 
mechanisms: (i) depletion of IN from virions thus precluding the formation of IN-vRNA complexes; ii) 
impairment of functional IN multimerization and as a result, indirect disruption of IN-vRNA binding; iii) 
direct disruption of IN-vRNA binding without substantially affecting IN levels or its inherent 
multimerization properties. Irrespective of how IN binding to vRNA is inhibited, all substitutions led to the 
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formation of eccentric viral particles. Taken together, our findings cement the view that IN binding to RNA 
accounts for the role of IN in accurate particle maturation.  
In regard to the first case (i) above, it was previously shown that IN deletion leads to the formation 
of eccentric particles11,27. Thus, it is reasonable to assume that missense mutations that decreased IN levels 
in virions phenocopy IN deletion viruses. While it is also possible that these substitutions additionally 
affected IN binding to vRNA or multimerization, we could not reliably address these possibilities due to 
the extremely low levels of these proteins in virions.  
Our results with different oligomeric states of WT IN show that the tetramers rather than dimers or 
monomers are able to effectively bind and bridge cognate RNA oligonucleotides (Figure 5A, B). Consistent 
with these observations, a number of substitutions  (V165A, K186E, K188E and K236E) that compromised 
IN tetramerization also exhibited reduced binding affinity to RNA and failed to bridge separate RNA 
oligonucleotides (Figure 5C, Figure 5-Figure Supplement 1). More pronounced effects observed with 
bridging vs. binding assays, suggest a greater importance of IN tetramerization for forming functionally 
critical IN-RNA condensates. It is possible that IN dimers can weakly bind RNA but they are unable to 
accommodate and bridge multiple RNA oligonucleotides. In contrast, IN tetramers can both bind with 
higher affinity and provide larger binding interface to recruit additional RNA molecules.  In turn, the ability 
of IN tetramers to bridge between different segments of viral RNA could be essential for formation of the 
stable IN-RNA condensates in virions. Consistent with this notion, all class II substitutions that 
compromised IN tetramerization also failed to form stable IN-RNA complex in virions (Figure 3B). The 
structural basis for IN binding to RNA is not yet known and it is possible that IN tetramers in the complex 
with viral RNA differ substantially from those bound to viral DNA within the intasome complex (Figure 
1). Nonetheless, our findings indicate the importance of IN tetramers for formation of productive IN-RNA 
complexes.  
Based on MS-based footprinting experiments in vitro, we previously found that positively charged 
residues within the CTD of IN (i.e. K264, K266, K273) directly contact RNA, as was also validated by 
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CLIP experiments28. Our findings here suggest that IN-vRNA contacts may extend to nearby basic residues 
within the CTD, such as R262 and R263, and perhaps more surprisingly, K34 within the IN NTD, as 
alterations of these residues did not prevent IN tetramerization (Figure 4A-B) but completely abolished IN-
vRNA binding in virions (Figure 3B) and reduced RNA-binding in vitro (Fig 5B-C). This raises the 
possibility of a second RNA-binding site in the IN NTD. Structural analysis of IN in complex with RNA 
will be essential to definitively determine how IN binds RNA as well as the precise multimeric species 
required for binding and bridging/condensation. 
The mechanism by which IN-vRNA interactions mediate the encapsidation of vRNPs inside the 
CA lattice remains unknown. One possibility is that the temporal coordination of proteolytic cleavage 
events during maturation is influenced by IN-vRNA interactions81,82. In this scenario, the assembly of the 
CA lattice may become out of sync with the compaction of vRNA by NC. Another possibility is that IN-
vRNA complexes nucleate the assembly of the CA lattice, perhaps by directly binding to CA. Notably, the 
biochemical assays performed herein show that class II IN substitutions do not appear to affect the assembly 
and stability of the CA lattice in vitro and in target cells. Although this finding is in disagreement with the 
previously observed morphological aberrations of the CA lattice present in eccentric particles26, it is 
possible that the biochemical experiments used herein lack the level of sensitivity required to quantitatively 
assess these aberrations or that the cryo-ET procedure impacts the structure of the CA lattice in particular 
in eccentric virions due to the absence of a packaged vRNP complex. A further possibility is that while the 
CA lattice in class II IN mutant virions may appear morphologically aberrant, they may still uncoat similar 
to WT virions in target cells. Further studies deciphering the crosstalk between IN-RNA interactions and 
CA assembly will be critical to our understanding of the role of IN in accurate virion maturation. 
While the mislocalization of the vRNA genome in eccentric particles can be accurately assessed by 
TEM analysis, precisely where IN is located in eccentric particles remains an open question. Earlier studies 
based on biochemical separation of core components from detergent-treated IN R269A/K273A virions 
indicated that IN may also mislocalize outside the CA lattice76. In this study, only two class II IN mutants 
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(K34A and R262A/R263A) demonstrated this phenotype (Figure 7A, B). It is intriguing that the bimodal 
distribution of IN in this experimental setting was only seen with IN mutants that directly inhibited IN 
binding to vRNA. A possible explanation for these observations is that improperly multimerized IN is 
retained within the CA lattice or in association with it. Alternatively, class II IN mutants may localize 
outside of the CA lattice but form dense aggregates and as a result migrate similar to WT IN. The fact that 
select class II IN mutants migrate similar to WT IN upon CA destabilization (Figure 7-Figure Supplement 
1A) strongly suggests the latter possibility.  
Although the basic aspects of virion maturation are conserved, particle morphologies are vastly 
different across retroviruses83,84. It is currently unknown whether IN molecules of other retroviruses 
regulate viral maturation through binding to vRNAs. Interestingly, mutations within the C-terminus of 
murine leukemia virus (MLV) IN can similarly cause defects in reverse transcription85,86, raising the 
possibility of a conserved role for IN in particle maturation and reverse transcription across retroviruses. 
 In conclusion, we have identified IN-vRNA binding as the underlying factor for the role of IN in 
virion morphogenesis. Despite relatively high barriers, drugs that inhibit the catalytic activity of IN do 
select for resistance, and additional drug classes that inhibit IN activity through novel mechanisms of action 
would be a valuable addition to currently available treatments. The finding that IN-vRNA interaction can 
be inhibited in multiple ways- by directly altering residues in the IN CTD or by altering IN multimerization 
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The pNLGP plasmid consisting of the HIV-1NL4-3 -derived Gag-Pol sequence inserted into the pCR/V1 
plasmid backbone87 and the CCGW vector genome plasmid carrying a GFP reporter under the control of 
the CMV promoter88,89 were previously described. The pLR2P-vprIN plasmid expressing a Vpr-IN fusion 
protein has also been previously described75. Mutations in the IN coding sequence were introduced into 
both the pNLGP plasmid and the HIV-1NL4-3  full-length proviral plasmid (pNL4-3) by overlap extension 
PCR. Briefly, forward and reverse primers containing IN mutations in the pol reading frame were used in 
PCR reactions with antisense and sense outer primers containing unique restriction endonuclease sites 
(AgeI-sense, NotI-antisense for NLGP and AgeI-sense, EcoRI-antisense for pNL4-3), respectively. The 
resulting fragments containing the desired mutations were mixed at 1:1 ratio and overlapped subsequently 
using the sense and antisense primer pairs. The resulting fragments were digested with the corresponding 
restriction endonucleases and cloned into pNLGP and pNL4-3 plasmids. IN mutations were introduced into 
the pLR2P-vprIN plasmid using the QuickChange Site-Directed Mutagenesis kit (Agilent Technologies). 
Presence of the desired mutations and absence of unwanted secondary changes were verified by Sanger 
sequencing. HIV-1 CA K203A substitution, which destabilizes the CA lattice78, was cloned into HIV-1NL4-
3  bearing class II IN mutations by conventional cloning. Generation of Gag-bZIP chimeras bearing the 
leucine zipper domain from the yeast GCN4 protein in place of NC, which facilitates Gag dimerization but 
does not bind RNA has been described before79,80. A version of this chimera was generated by replacing 
NC with a NotI restriction site and cloning of the PCR-amplified GCN4-bZIP in its place. Class II IN 
mutants were subsequently cloned into this backbone by the QuickChange Site-Directed Mutagenesis kit 
(Agilent Technologies). 
 
Cells and viruses 
All cell lines were originally obtained from American Type Culture Collection and NIH AIDS Reagents 
where STR profiling was performed. All cell lines are regularly checked for mycoplasma contamination 
using the MycoAlert mycoplasma detection kit (Lonza) and verified to be free of contamination during the 
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course of these studies. HEK293T cells (ATCC CRL-11268) were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum. Single-cycle GFP reporter viruses 
pseudotyped with vesicular stomatitis virus G protein (VSV-G) were produced by transfection of HEK293T 
cells with pNLGP-derived plasmids, the CCGW vector genome carrying GFP, and VSV-G expression 
plasmid at a ratio of 5:5:1, respectively, using polyethyleneimine (PolySciences, Warrington, PA). Full-
length viruses pseudotyped with VSV-G were produced by transfecting HEK293T cells with the pNL4-3-
derived plasmids and VSV-G plasmid at a ratio of 4:1 (pNL4-3:VSV-G).  
 
Immunoblotting 
Viral and cell lysates were resuspended in sodium dodecyl sulfate (SDS) sample buffer and separated by 
electrophoresis on Bolt 4-12% Bis-Tris Plus gels (Life Technologies), blotted onto nitrocellulose 
membranes and probed overnight at 4°C with the following antibodies in Odyssey Blocking Buffer (LI-
COR): mouse monoclonal anti-HIV p24 antibody (183-H12-5C, NIH AIDS reagents), mouse monoclonal 
anti-HIV integrase antibody70, rabbit polyclonal anti-HIV integrase antibody raised in-house against Q44-
LKGEAMHGQVD-C56 peptide and hence unlikely to be affected by the substitutions introduced into IN 
in this study, rabbit polyclonal anti-HIV-1 reverse transcriptase antibody (6195, NIH AIDS reagents), rabbit 
polyclonal anti-Vpr antibody (11836, NIH AIDS Reagents), rabbit polyclonal anti-MA antibody (4811, 
NIH AIDS Reagents). Membranes were probed with fluorophore-conjugated secondary antibodies (LI-
COR) and scanned using a LI-COR Odyssey system. IN and CA levels in virions were quantified using 
Image Studio software (LI-COR). Alternatively, antibody incubations were done using 5% non-fat dry milk 
and membranes were probed with HRP-conjugated secondary antibodies and developed using 
SuperSignalTM West Femto reagent (Thermo-Fisher).  
 
CLIP experiments 
CLIP experiments were conducted as previously described28,91,92. Cell-free HIV-1 virions were isolated 
from transfected HEK293T cells. Briefly, cells in 15-cm cell culture plates were transfected with 30 μg 
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full-length proviral plasmid (pNL4-3) DNA containing the WT sequence or indicated pol mutations within 
the IN coding sequence. Cells were grown in the presence of 4-thiouridine for 16 hr prior to virus harvest. 
Two days post transfection cell culture supernatants were collected and filtered through 0.22 µm filters and 
pelleted by ultracentrifugation through a 20% sucrose cushion using a Beckman SW32-Ti rotor at 28,000 
rpm for 1.5 hr at 4°C. Virus pellets were resuspended in phosphate-buffered saline (PBS) and UV-
crosslinked. Following lysis in RIPA buffer, IN-RNA complexes were immunoprecipitated using a mouse 
monoclonal anti-IN antibody70. Bound RNA was end-labeled with γ-32P-ATP and T4 polynucleotide kinase. 
The isolated protein-RNA complexes were separated by SDS-PAGE, transferred to nitrocellulose 
membranes and exposed to autoradiography films to visualize RNA. Lysates and immunoprecipitates were 
also analyzed by immunoblotting using antibodies against IN. 
 
IN multimerization in virions 
HEK293T cells grown on 10-cm dishes were transfected with 10 μg pNL4-3 plasmid DNA containing the 
WT sequence or indicated pol mutations within IN coding sequence. Two days post-transfection cell-free 
virions collected from cell culture supernatants were pelleted by ultracentrifugation through a 20% sucrose 
cushion using a Beckman SW41-Ti rotor at 28,000 rpm for 1.5 hr at 4°C. Pelleted virions were resuspended 
in 1X PBS and treated with ethylene glycol bis(succinimidyl succinate) (EGS) (ThermoFisher Scientific), 
a membrane permeable crosslinker, at a concentration of 1 mM for 30 min at room temperature. 
Crosslinking was stopped by addition of SDS sample buffer. Samples were subsequently separated on 3-
8% Tris-acetate gels and analyzed by immunoblotting using a mouse monoclonal anti-IN antibody70. 
 
Size exclusion chromatography (SEC)  
All of the mutations were introduced into a plasmid backbone expressing His6 tagged pNL4-3-derived IN 
by QuikChange site directed mutagenesis kit (Agilent)60. His6 tagged recombinant pNL4-3 WT and mutant 
INs were expressed in BL21 (DE3) E. coli cells followed by nickel and heparin column purification as 
described previously60,93. Recombinant WT and mutant INs were analyzed on Superdex 200 10/300 GL 
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column (GE Healthcare) with running buffer containing 20 mM HEPES (pH 7.5), 1 M NaCl, 10% glycerol 
and 5 mM BME at 0.3 mL/min flow rate. The proteins were diluted to 10 µM with the running buffer and 
incubated for 1 hr at 4°C followed by centrifugation at 10,000g for 10 min. Multimeric form determination 
was based on the standards including bovine thyroglobulin (670,000 Da), bovine gamma-globulin (158,000 
Da), chicken ovalbumin (44,000 Da), horse myoglobin (17,000 Da) and vitamin B12 (1,350 Da). 
 
Analysis of IN-RNA binding in vitro 
Following SEC of IN as above, individual fractions of tetramer, dimer and monomer forms were collected 
and their binding to TAR RNA was analyzed by an Alpha screen assay as described previously28. Briefly, 
100 nM His6 tagged IN fractions (tetramer, dimer and monomer) were incubated with nickel acceptor beads 
while increasing concentrations of biotinylated-TAR RNA was incubated with streptavidin donor beads in 
buffer containing 100 mM NaCl, 1 mM MgCl2, 1 mM DTT, 1 mg/mL BSA, 25 mM Tris (pH 7.4). Followed 
by 2-h incubation at 4°C, they were mixed and the reading was taken after 1 hr incubation at 4°C by 
PerkinElmer Life Sciences Enspire multimode plate reader. The Kd values were calculated using OriginLab 
software. 
 
AlphaScreen-based RNA bridging assays 
The RNA bridging property of IN was analyzed by AlphaScreen-based assay as described28. Briefly, equal 
concentrations (1 nM) of two synthetic TAR RNA oligonucleotides labeled either with biotin or DIG were 
mixed and then streptavidin donor and anti-DIG acceptor beads at 0.02 mg/mL concentration were supplied 
in a buffer containing 100 mM NaCl, 1 mM MgCl2, 1 mM DTT, 1 mg/mL BSA and 25 mM Tris (pH 7.4). 
After 2 hr incubation at 4 °C, indicated concentrations of IN were added to the reaction mixture and 
incubated further for 1.5 hr at 4 °C.  AlphaScreen signals were recorded with a PerkinElmer Life Sciences 




Virus production and transmission electron microscopy 
Cell-free HIV-1 virions were isolated from transfected HEK293T cells. Briefly, cells grown in two 15-cm 
cell culture plates (107 cells per dish) were transfected with 30 µg full-length proviral plasmid (pNL4-3) 
DNA containing the WT sequence or indicated pol mutations within IN coding sequence using PolyJet 
DNA transfection reagent as recommended by the manufacturer (SignaGen Laboratories). Two days after 
transfection, cell culture supernatants were filtered through 0.22 µm filters and pelleted by 
ultracentrifugation using a Beckman SW32-Ti rotor at 26,000 rpm for 2 hr at 4 °C. Fixative (2.5% 
glutaraldehyde, 1.25% paraformaldehyde, 0.03% picric acid, 0.1 M sodium cacodylate, pH 7.4) was gently 
added to resulting pellets, and samples were incubated overnight at 4 °C. The following steps were 
conducted at the Harvard Medical School Electron Microscopy core facility. Samples were washed with 
0.1 M sodium cacodylate, pH 7.4 and postfixed with 1% osmium tetroxide /1.5% potassium ferrocyanide 
for 1 h, washed twice with water, once with maleate buffer (MB), and incubated in 1% uranyl acetate in 
MB for 1 h. Samples washed twice with water were dehydrated in ethanol by subsequent 10 minute 
incubations with 50%, 70%, 90%, and then twice with 100%. The samples were then placed in 
propyleneoxide for 1 hr and infiltrated overnight in a 1:1 mixture of propyleneoxide and TAAB Epon 
(Marivac Canada Inc.). The following day the samples were embedded in TAAB Epon and polymerized at 
60 °C for 48 h. Ultrathin sections (about 60 nm) were cut on a Reichert Ultracut-S microtome, transferred 
to copper grids stained with lead citrate, and examined in a JEOL 1200EX transmission electron microscope 
with images recorded on an AMT 2k CCD camera. Images were captured at 30,000x magnification, and 
over 100 viral particles per sample were counted by visual inspection. 
 
Equilibrium density sedimentation of virion core components in vitro 
Equilibrium density sedimentation of virion core components was performed as previously described76. 
Briefly, HEK293T cells grown in 10-cm cell culture plates were transfected with 10 μg pNLGP plasmid 
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DNA containing the WT sequence or indicated pol mutations within IN coding sequence. Two days post-
transfection cell-free virions collected from cell culture supernatants were pelleted by ultracentrifugation 
through a 20% sucrose cushion using a Beckman SW41-Ti rotor at 28,000 rpm for 1.5 hr at 4 °C. Pelleted 
viral-like particles were resuspended in PBS and treated with 0.5% Triton X-100 for 2 min at room 
temperature. Immediately after, samples were layered on top of 30-70% linear sucrose gradients prepared 
in 1X STE buffer (100 mM NaCl, 10 mM Tris-Cl (pH 8.0), 1 mM EDTA) and ultracentrifuged using a 
Beckman SW55-Ti rotor at 28,500 rpm for 16 hr at 4 °C. Fractions (500 μL) collected from the top of the 
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2.7 SUPPLEMENTAL FIGURES AND TABLES 
Supplemental Table 1: Quantitation of IN in virions as measured by western blotting 
IN mutant IN signal (%) SD IN mutant IN signal (%) SD 
WT 100 N/A K186E 63.2 16.4 
H12N ND N/A R187A 34.4 24.5 
K14A 40.5 10.3 K188E 45.8 26.3 
N18I 16.7 3.1 R199A 41.1 19.2 
K34A 32.6 6.9 Q214L/Q216L 31.7 6.3 
E87A 31.4 16.1 
 
K215A/K219A 47.7 20.4 
E96A 38.4 31.2 R228A 50.2 26.4 
Y99A 22.0 10.3 K236E 37.4 14.0 
K103E 6.8 2.3 L241A 41.4 12.4 
W108R 2.7 0.3 L242A 13.7 3.5 
V165A 55.6 32.8 K258A 36.7 19.7 
F185K 2.5 1.6 V260E 6.0 4.0 
K186A 69.4 27.9 R262A/R263A 52.9 7.0 
For each experiment IN signal was normalized to CA signal for each virus, and the resulting value 
compared to that of WT (set at 100%.) Reported values are the average value (as percent of WT) and 
standard deviation (SD) between 4 independent experiments. Mutants with less than 20% IN signal of WT 




Figure 2-Figure Supplement 1. Characterization of the replication defects of class II IN mutant 
viruses. (A) Reverse-transcriptase activity measured in HIV-1NL4-3 virion lysates. For each repetition RT 
activities for the IN mutants are expressed relative to the WT (set to 1.) Columns show average of two 
independent experiments (open circles) and error bars represent standard deviation. (B) Representative 
immunoblot analysis of Vpr-IN fusion constructs in cell lysates. HEK293T cells were co-transfected with 
the HIV-1NL4-3 IND116N proviral plasmid along with Vpr-IN expression plasmids encoding for the indicated 
IN substitutions or an empty vector control.  Expression of Vpr-IN constructs in cell lysates was detected 










































































































Figure 4-Figure Supplement 1. Multimerization properties of class II IN mutants. Immunoblot 
analyses of IN multimers in virions. Purified WT or IN mutant HIV-1NL4-3 virions were treated with 1 mM 
EGS, and virus lysates analyzed by immunoblotting using antibodies against IN following separation on 
6% Tris-acetate gels. Position of monomers (M), dimers (D), and tetramers (T) are indicated by arrows. 
Representative image of one of three independent experiments is shown. 
 
Supplementary Table 2: Predominant multimeric species of mutant INs in vitro as assessed by SEC. 
IN mutant Multimeric species Reference 
H12N 
 
Dimer or dimer/monomer mixture Hare et al., PLoS Pathog, 2009 
K14A 
 
Dimer McKee et. al., J Biol Chem, 2008 
E87A Dimer Kessl et al., Mol Pharmacol, 2009 
F185K 
 
Dimer Pandey et. al., Biochem, 2011 
K186A Dimer McKee et. al., J Biol Chem, 2008; 
Houwer et. al., J Biol Chem, 2012 
K186E  
 
Dimer or dimer/monomer mixture Hare et al., PLoS Pathog, 2009 
R187A Dimer McKee et. al., J Biol Chem, 2008; 
Houwer et. al., J Biol Chem, 2012 
L241A 
 
Dimer Luztke and Plasterk, J Vir, 1998 
L242A 
 
Dimer/tetramer mixture, shifted to dimer Luztke and Plasterk, J Vir, 1998 




















































































Figure 5-Figure Supplement 1. RNA-binding properties of Class II IN mutants in vitro. (A-D) 
Analysis of 100 nM WT or mutant INs binding to biotinylated TAR RNA by AlphaScreen assay. Graphed 
data is the average of three independent experiments and error bars indicate standard deviation. 
 























WT IN Kd= 0.68±0.02 nM
K34A IN Kd= 1.69±0.23 nM




















WT IN Kd= 0.58±0.05 nM
V165A IN Kd= 1.85±0.05 nM























WT IN Kd: 1.56±0.06 nM
K186E IN Kd: 5.71±0.2 nM
K188E IN Kd: 5.23±0.1 nM
D
WT IN Kd: 0.75±0.04 nM
K236E IN Kd: 3.71±0.3 nM

























Figure 7-Figure Supplement 1. Biochemical properties of Class II IN mutants in virions upon CA 
destabilization and in the absence of NC. (A) Immunoblot analysis of sedimentation profiles of IN in 
HIV-1NLGP CAK203A mutant virions. In addition to the CAK203A mutation, class II mutations were introduced 
in IN. Purified virions were stripped of the viral envelope using 0.5% Triton X-100 and analyzed by 
equilibrium density centrifugation as detailed in Materials and Methods. Ten fractions collected from the 
top of the gradients were analyzed by immunoblotting using antibodies against IN or CA. Representative 
images from one of two independent experiments are shown. (B) Immunoblot analysis of sedimentation 
profiles of WT vs. class II IN mutants from HIV-1NL4-3 bZIP virions. Purified virions were analyzed by 
equilibrium density centrifugation, ten fractions were collected from the top of the gradients and 
subsequently analyzed by immunoblotting using antibodies against IN or CA. Representative images from 
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Mutations in human immunodeficiency virus 1 (HIV-1) integrase (IN) can have a wide range of effects on 
virus replication. Class II substitutions are defined as those that inhibit the viral life cycle at steps other than 
integration, and often block virus replication either at or prior to reverse transcription. However, the 
mechanism for this defect has not been elucidated. Here we demonstrate that all tested class II IN 
substitutions lead to premature degradation of the viral genome and IN in target cells, likely as a result of 
the mislocalization of the genome and IN outside the viral capsid. Our findings provide an explanation for 
why eccentric particles are unable to complete the HIV-1 life cycle. 
 
3.2 INTRODUCTION 
In mature HIV-1 virions the two copies of single-stranded RNA genome are condensed and coated by the 
nucleocapsid protein (NC), together forming the viral ribonucleoprotein complex (vRNP.) The vRNP and 
viral replicative enzymes reverse transcriptase (RT) and integrase (IN) are enclosed inside of a conical 
capsid lattice made up of many monomers of capsid (CA) protein, which is released into the cytoplasm of 
the target cell during viral entry1-3. After entry, the single-stranded viral RNA (vRNA) is reverse-transcribed 
by RT into double-stranded viral DNA (vDNA)4,5. RT initiates reverse transcription by using the positive-
stranded vRNA as a template and the host Lys3 tRNA as a primer to synthesize a minus-strand DNA5. As 
RT synthesizes the vDNA the RNA template is degraded except for a purine-rich sequence known as the 
polypurine tract, which RT uses a primer for synthesis of the plus-strand DNA while using the completed 
minus-strand DNA as a template5.  After reverse transcription is completed a multimer of IN binds either 
end of the linear vDNA and inserts it into the host chromosome by IN as a provirus6. 
A number of substitutions in IN (class II IN substitutions) or deletion of IN can interfere with virion 
morphogenesis and lead to morphologically aberrant viral particles with the vRNP mislocalized outside the 
capsid within the particles, referred to as eccentric viral particles7-14. Treating producer cells with a class of 
IN-targeting compounds, allosteric integrase inhibitors (ALLINIs), leads to similar morphological defects 
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in virions8,9,15-22. Intriguingly, eccentric virions generated by class II IN substitutions or ALLINI treatment 
are defective for reverse transcription in target cells7-10,12,13,15,16,18,21,23-45 despite containing equivalent levels 
of RT and vRNA genome as wild type (WT) particles8,46. In addition, neither the condensation of the viral 
genome by NC8,46 nor its priming46 appear to be affected. Varying explanations have been offered for these 
observations. One possibility is that direct interaction between IN and RT is required for reverse 
transcription, a hypothesis that is bolstered by the finding that IN interacts with RT in vitro, and IN 
mutations that abolish this interaction also prevent reverse transcription in cells39,45,47. It is also possible that 
while vRNA is mislocalized outside the viral capsid in eccentric particles, RT is not, and physical separation 
of RT from vRNA underlies the defect in reverse transcription48. We and others have recently shown that 
premature loss of the viral genome and IN, as well as spatial separation of RT from vRNPs, may underlie 
the reverse transcription defect observed in eccentric viruses generated in the presence of ALLINIs or the 
class II IN R269A/K273A substitutions48,49. These findings support a model in which enclosure within the 
capsid lattice or IN binding to vRNA itself is necessary to protect viral components from the host 
environment upon entering the target cell. However, whether the premature loss of the viral genome and 
IN is a universal outcome of other class II IN substitutions is unknown.  
 In this work, we aimed to determine why eccentric viral particles produced by class II IN 
substitutions are blocked early in the viral life cycle. We found that all class II IN substitutions examined 
led to premature loss of the vRNA genome as well as IN itself in target cells. Additionally, there was a 
spatial separation of RT and CA from the vRNPs in target cells. Taken together, our findings suggest that 
a common mechanism underlies the loss of infectivity in class II IN mutant viruses and highlights the 








Class II IN mutant viruses are blocked early in the viral life cycle 
Many class II IN substitutions are known to inhibit viral replication, and in particular prevent the completion 
of reverse transcription in target cells7-10,12,13,15,16,18,23-45,50. To test if the defect in reverse transcription is a 
common trait of class II IN substitutions, we first measured the titers of the class II IN mutant viruses 
previously generated (Chapter 2, Fig. 1). With the exception of E96A, nearly all of the IN substitutions 
reduced virus titers at least 100-fold compared to the WT (Figure 1A). We next measured the amount of 
vDNA in infected cells, and found a similar reduction in the amount of reverse-transcribed vDNA (Figure 
1B). Although these results demonstrated a block in viral replication prior to integration, either at or before 
reverse transcription, we also sought to test the effects of the substitutions on the catalytic activity of IN. 
To assess whether the substitutions prevented IN from catalyzing the integration reaction in target cells, we 
trans-complemented a class I IN mutant virus defective for integration (NL4-3 IN D116N)7,51 with each 
class II IN mutant protein using a previously described Vpr-IN fusion strategy52,53. In line with previous 
reports25,26,33, the class II mutant IN molecules had variable levels of catalytic activity as assessed by their 
ability to rescue replication of the NL4-3 IN D116N virus. All Vpr-IN fusion proteins, except for the H12N 
mutant which likely decreased the stability of the Vpr-IN fusion protein, were expressed at similar levels 
in cells (Figure 1-Figure Supplement 1). We found that K14A, E96A, Y99A, K103A, V165A, R187A, 
K188E R199A, K236E, and R269A/R273A IN mutants trans-complemented a catalytically inactive IN at 
levels similar to the WT, whereas W108R, R228A, and V260E mutants were unable to do so (Figure 1C-
D). The inability of W108R, R228A, and V260E mutants to trans-complement implies that they are 
impaired for integration, a result in line with previous observations54,55. The remainder of the IN mutants 
restored integration, albeit at significantly lower than WT levels (Figure 1C-D). These results suggest that 
the majority of the class II mutant INs retain structural integrity and at least partial catalytic activity in the 
presence of a complementing IN protein. Cumulatively, the data shows that class II IN substitutions 
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Figure 1: Class II IN mutant viruses are blocked early in the viral life cycle. (A) Infectious titers of 
WT or IN mutant HIV-1NL4-3 viruses in cell culture supernatants were determined on TZM-bl indicator 
cells. Titer values are expressed relative to WT (set to 1). Columns show average of five independent 
experiments (open circles) and error bars represent standard deviation (****P < 0.0001, by one-way 
ANOVA with Dunnett’s multiple comparison test). (B) Relative quantity of reverse-transcribed HIV-1 
DNA in MT-4 target cells infected with HIV-1NL4-3 at 6 hpi. Quantities of vDNA are expressed relative to 
WT (set to 1). Columns show average of three independent experiments (open circles) and error bars 
represent standard deviation (****P < 0.0001, by one-way ANOVA with Dunnett’s multiple comparison 
test). (C) Representative growth curve of HIV-1NL4-3 IND116N viruses trans-complemented with class II 
mutant IN proteins in cell culture. Y-axis indicates fold increase in virion yield over day 0 as measured by 
RT activity in culture supernatants. HIV-1NL4-3 IND116N viruses that were trans-complemented with WT IN, 
class II mutant INs, IND116N, or an empty vector are denoted as red, black, dark blue and light blue lines 
respectively. Representative plot from one of three independent experiments. (D) Fold increase in virions 
in culture supernatants at 4 dpi, as measured by RT activity in culture supernatants. Trans-complementation 
of the HIV-1NL4-3 IND116N virus with mutant IN molecules restored particle release to levels comparable to 














































































































































































































































































































































































show average of three independent experiments (open circles) and error bars represent standard deviation 
(*P < 0.05 and **P < 0.01, by paired t test between individual mutants and WT). 
 
Viral RNA and IN is prematurely lost from cells infected with Class II IN mutant viruses 
We have previously shown that vRNA and IN are prematurely lost from cells infected with the 
R269A/K273A class II IN mutant48. Given that eccentric vRNP localization is a common feature of class 
II IN mutant viruses (Chapter 2, Figure 6), we asked whether loss of vRNA in target cells is a common 
outcome for other class II IN mutant viruses. In contrast to the vRNA, the majority of mutant IN molecules 
appeared to remain associated with higher-order CA in virions (Chapter 2, Figure 7), and so we also wanted 
to test whether they would be protected from premature degradation in infected cells. 
 The fates of viral core components in target cells were tracked using a previously described 
biochemical assay56. For these experiments we utilized pgsA-745 cells (pgsA), which lack surface 
glycosaminoglycans, and likely as a result can be very efficiently infected by VSV-G-pseudotyped viruses 
in a synchronized fashion. PgsA cells were infected with WT or IN mutant viruses bearing substitutions 
that inhibited IN-vRNA interactions directly and may lead to mislocalization of IN in virions (i.e. K34A, 
R262A/R263A, R269A/K273A) or indirectly through aberrant IN multimerization and did not appear to 
grossly affect IN localization in virions (i.e. E87A, V165A) (Figure 2A). Two hours post infection, post-
nuclear lysates were separated on linear sucrose gradients, and fractions collected from gradients were 
analyzed for viral proteins (CA, IN, RT) and vRNA by immunoblotting and Q-PCR-based assays, 
respectively.  
 As previously reported48,56, in cells infected with WT viruses, IN, RT, vRNA and a fraction of CA 
comigrated in sucrose fractions 6-8, representing active RTCs (Figure 2B-E). Note that a large fraction of 
CA migrated in the top two soluble sucrose fractions representing CA that had dissociated from the core as 
a result of uncoating or CA that was packaged into virions but not incorporated into the capsid lattice57,58. 
Notably, in cells infected with class II IN mutant viruses, equivalent levels of CA (Figure 2B) and RT 
(Figure 2D) remained in the denser fractions, whereas IN (Figure 2C) and vRNA (Figure 2E) were 
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substantially reduced. Loss of vRNA and IN from dense fractions, without any corresponding increase in 
the top fractions containing soluble proteins and RNA, suggest their premature degradation and/or 




Figure 2. Premature loss of vRNA and IN from class II IN mutant viruses upon infection of target 
cells. (A) Locations of the class II IN substitutions K34A, E87A, V165A and R262A/R263A displayed on 



























































































































Substitutions are color coded based on whether they may cause mislocalization of IN in virions (black) or 
not (blue.) (B-E) PgsA-745 cells were infected with WT or IN mutant HIV-1 virions and fates of viral core 
components were analyzed 2 hpi. Fractions were analyzed for the presence of CA (B) and IN (C) by 
immunoblotting and for RT activity (D) and vRNA (E) by Q-PCR. Immunoblots are representative of three 
independent experiments. Graphed data in (D) and (E) is the average of three independent experiments with 
error bars indicating standard deviation (*P < 0.05 and **P < 0.01, by repeated measures one-way 
ANOVA.) (F) Representative images of pgsA-745 cells infected with WT or IN mutant HIV-1NL4-3 viruses 
0 and 2 hpi. Cells were stained for vRNA (green) and nuclei (blue) as detailed in Materials and Methods. 
(G) Quantification of vRNA remaining in cells infected with WT or IN mutant HIV-1NL4-3 viruses at 2 hpi. 
Values are the percent of vRNA remaining at 2 hpi compared to at 0 hpi. Columns show average of three 
independent experiments (open circles) and error bars represent standard deviation (*P < 0.05 and **P < 
0.01, by one-way ANOVA with Dunnett’s multiple comparison test.) 
 
 We next employed a complementary microcopy-based assay59 in the context of full-length viruses 
to corroborate these findings. Advantages of this approach over biochemical fractionation experiments 
include the ability to track HIV-1 vRNA at the single-cell level with a high degree of specificity (Figure 2-
Figure Supplement 1A), determine its subcellular localization, and to side-step possible post-processing 
artifacts associated with biochemical fractionation. Cells were synchronously infected with VSV-G 
pseudotyped HIV-1NL4-3 in the presence of nevirapine to prevent vRNA loss due to reverse transcription, 
and vRNA levels associated with cells immediately following synchronization (0 hour) and 2 hours post-
infection were evaluated59. In WT-infected cells, vRNA was clearly visible immediately after infection 
(Figure 2F). Two hours post-infection, cell associated vRNA had fallen to 60-80% of starting levels (Figure 
2F-G), likely as the result of some viruses failing to enter or perhaps being degraded after entry. However, 
a significant proportion of vRNA was still readily detectable. In contrast, in cells infected with the IN 
mutant viruses the reduction in vRNA was greater, and by 2 hours post-infection only 30-40% remained 
(Figure 2F-G, Figure 2 Supplement 1B). These results support the conclusion from the biochemical 
fractionation experiments that vRNA is prematurely lost from cells infected with class II IN mutant viruses. 
 Finally, we tested whether our findings held true in physiologically relevant human cells. MT-4 T 
cells were synchronously infected with WT or class II IN mutant VSV-G pseudotyped HIV-1NL4-3 in the 
presence of nevirapine. Cells were collected immediately after synchronization (0 hour), 2 and 6 hours post-
infection, and the quantity of vRNA measured by Q-PCR. In line with the above findings, vRNA levels 
decreased at a faster rate with the class II IN mutants as compared to WT viruses, with half as much cell-
 
 74 
associated vRNA remaining at 2 and 6 hours post-infection for the class II IN mutants (Figure 3A). Treating 
cells with ammonium chloride to prevent fusion of the VSV-G pseudotyped viruses rescued vRNA loss, 
and vRNA from WT and mutant viruses were retained at equal levels, indicating that the loss of vRNA is 
dependent on entry into the target cell (Figure 3B). These findings agree with the previous experiments and 
demonstrate that class II IN substitutions lead to the premature loss of vRNA genome also in human T cells. 
 
Figure 3. Loss of vRNA from class II IN mutant viruses upon infection of target cells is dependent on 
viral entry. (A) Fraction of viral RNA remaining after 2 and 6 hpi compared to the quantity measured at 0 
hpi. MT-4 cells were synchronously infected with VSV-G pseudotyped HIV-1NL4-3 viruses and at each 
timepoint samples of infected cultures were taken for analysis. Viral RNA levels in samples were measured 
by Q-PCR and normalized to the levels of GAPDH mRNA. Data points are the average of five independent 
experiments with error bars indicating standard error of the mean. (B) Fraction of viral RNA remaining 
after 2 and 6 hpi compared to the quantity measured at 0 hpi as above. MT-4 cells were synchronously 
infected with VSV-G pseudotyped HIV-1NL4-3 viruses and incubated in the presence of 50 mM ammonium 
chloride for 6 hrs. Data points are the average of three independent experiments with error bars indicating 
standard error of the mean. 
 
3.4 DISCUSSION 
Our studies provide the mechanistic basis for how diverse class II IN mutations result in a common block 
in viral replication. We propose premature degradation of the exposed vRNA and IN, as well as separation 
of RT from the vRNA, underlies the reverse transcription defect seen in class II IN mutant viruses. In 
addition to class II IN mutations, it is likely that our findings also apply to eccentric viruses produced by 
















































Several studies to date have found that when class II IN mutant viruses or ALLINI-treated viruses 
enter target cells, vRNA and IN itself is lost from the cells using both biochemical48 and microscopy-based 
assays49. However, this is the first study to our knowledge to characterize the replication defects of a large 
and diverse panel of class II IN mutant viruses side-by-side. Our results and those of others indicate that 
the premature loss of vRNA and IN in target cells is a common result of eccentric virion morphology. 
Interestingly, mutations in CA that destabilize the capsid lattice in vitro also block reverse transcription in 
target cells60-63, and treating producer cells with a CA-targeting compound leads to the generation of 
eccentric viral particles defective for reverse transcription64, much like viral particles produced in the 
presence of ALLINIs. Finally, destabilizing CA mutations lead to the premature loss of vRNA and IN from 
target cells65, just like class II IN mutations. Taken together, these findings argue that proper encapsidation 
within the viral core is necessary to protect vRNA and viral replicative proteins from the host cell 
environment, and when unprotected by the viral capsid, vRNA and IN are either passively or actively 
degraded. 
A mechanism responsible for the loss of vRNA and IN in target cells has yet to be defined. It is 
possible that the high AU-content of HIV-1 vRNA makes it inherently unstable66-68, in a manner similar to 
that of cellular mRNAs that encode cytokines and growth factors69. It is also possible that when ectopically 
expressed alone in cells, IN undergoes proteasomal degradation70-74, and knockdown of a cellular 
component of the ubiquitin-conjugation system, E3 RING ligase TRIM33, enhances HIV-1 infection and 
replication in cells71. However, another study found that during infection with eccentric viral particles, the 
loss of vRNA and IN was proteasome-independent48. Future studies are warranted to determine the precise 
mechanism of vRNA and IN degradation upon their premature exposure. 
In addition to preventing premature degradation of vRNA and IN, the CA lattice may also play an 
important role in shielding viral core components from host immune recognition. Mutating the HIV-1 CA 
to prevent its interaction with cellular factors leads to activation of innate immune responses and cytokine 
production in infected dendritic cells75 and activation of a type 1 interferon response in infected monocyte-
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derived macrophages76, suggesting that the CA lattice is important for recruiting cellular proteins to cloak 
viral components from detection. While it is important to note that infected dendritic cells appear to detect 
reverse-transcribed viral DNA through the cytosolic DNA sensor cGAS75, innate cytokine expression is 
also elicited in peripheral blood mononuclear cells transfected with purified HIV-1 RNA77, demonstrating 
that HIV-1 RNA does have the potential to trigger immune activation. 
 In conclusion, we have identified the premature loss of the vRNA genome and IN, as well as spatial 
separation of the vRNA and RT, as probable underlying causes for block in virus replication seen in class 
II IN mutant viruses. Our findings elucidate why proper virion morphology is important for viral infectivity, 
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The pNLGP plasmid consisting of the HIV-1NL4-3 -derived Gag-Pol sequence inserted into the pCR/V1 
plasmid backbone78 and the CCGW vector genome plasmid carrying a GFP reporter under the control of 
the CMV promoter79,80 were previously described. The pLR2P-vprIN plasmid expressing a Vpr-IN fusion 
protein has also been previously described53. Mutations in the IN coding sequence were introduced into 
both the pNLGP plasmid and the HIV-1NL4-3  full-length proviral plasmid (pNL4-3) by overlap extension 
PCR. Briefly, forward and reverse primers containing IN mutations in the pol reading frame were used in 
PCR reactions with antisense and sense outer primers containing unique restriction endonuclease sites 
(AgeI-sense, NotI-antisense for NLGP and AgeI-sense, EcoRI-antisense for pNL4-3), respectively. The 
resulting fragments containing the desired mutations were mixed at 1:1 ratio and overlapped subsequently 
using the sense and antisense primer pairs. The resulting fragments were digested with the corresponding 
restriction endonucleases and cloned into pNLGP and pNL4-3 plasmids. IN mutations were introduced into 
the pLR2P-vprIN plasmid using the QuickChange Site-Directed Mutagenesis kit (Agilent Technologies). 
Presence of the desired mutations and absence of unwanted secondary changes were verified by Sanger 
sequencing. 
 
Cells and viruses 
All cell lines were originally obtained from American Type Culture Collection and NIH AIDS Reagents 
where STR profiling was performed. MT-4 cells were additionally subjected to STR profiling at 
Washington University School of Medicine Genome Engineering and iPSC center. All cell lines are 
regularly checked for mycoplasma contamination using the MycoAlert mycoplasma detection kit (Lonza) 
and verified to be free of contamination during the course of these studies. HEK293T cells (ATCC CRL-
11268) and HeLa-derived TZM-bl cells (NIH AIDS Reagent Program) were maintained in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum. MT-4 cells were maintained in 
RPMI 1640 medium supplemented with 10% fetal bovine serum. CHO K1-derived pgsA-745 cells (CRL-
2242, ATCC) that lack a functional xylosyltransferase enzyme and as a result do not produce 
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glycosaminoglycans were maintained in Dulbecco’s modified Eagle’s / F12 (1:1) media supplemented with 
10% fetal bovine serum and 1 mM L-glutamine. Single-cycle GFP reporter viruses pseudotyped with 
vesicular stomatitis virus G protein (VSV-G) were produced by transfection of HEK293T cells with 
pNLGP-derived plasmids, the CCGW vector genome carrying GFP, and VSV-G expression plasmid at a 
ratio of 5:5:1, respectively, using polyethyleneimine (PolySciences, Warrington, PA). Full-length viruses 
pseudotyped with VSV-G were produced by transfecting HEK293T cells with the pNL4-3-derived 
plasmids and VSV-G plasmid at a ratio of 4:1 (pNL4-3:VSV-G).  
 
Immunoblotting 
Viral and cell lysates were resuspended in sodium dodecyl sulfate (SDS) sample buffer and separated by 
electrophoresis on Bolt 4-12% Bis-Tris Plus gels (Life Technologies), blotted onto nitrocellulose 
membranes and probed overnight at 4°C with the following antibodies in Odyssey Blocking Buffer (LI-
COR): mouse monoclonal anti-HIV p24 antibody (183-H12-5C, NIH AIDS reagents) and mouse 
monoclonal anti-HIV integrase antibody81. For analysis of the fates of core components in infected cells, 
antibody incubations were done using 5% non-fat dry milk. Membranes were probed with HRP-conjugated 
secondary antibodies and developed using SuperSignalTM West Femto reagent (Thermo-Fisher).  
 
Analysis of reverse transcription products in infected cells 
MT-4 cells were grown in 24-well plates and infected with VSV-G pseudotyped pNL4-3 viruses (either 
WT or class II IN mutant) at a multiplicity of infection (MOI) of 2 in the presence of polybrene. Six hr 
post-infection cells were collected, pelleted by brief centrifugation, and resuspended in PBS. DNA was 
extracted from cells using the DNeasy Blood and Tissue Kit (Qiagen) as per kit protocol. Quantity of HIV-






Vpr-IN transcomplementation experiments 
A class I IN mutant virus (HIV-1NL4-3 IND116N) was trans-complemented with class II mutant IN proteins as 
described previously53. Briefly, HEK293T cells grown in 24-well plates were co-transfected with a 
derivative of the full-length HIV-1NL4-3 proviral plasmid bearing a class I IN substitution (pNL4-3D116N), 
VSV-G, and derivatives of the pLR2P-vprIN plasmid bearing class II IN mutations at a ratio of 6:1:3. Two 
days post-transfection cell-free virions were collected from cell culture supernatants. Integration capability 
of the trans-complemented class II IN mutants was tested by infecting MT-4 cells and measuring the yield 
of progeny virions in cell culture supernatants over a 6-day period as described previously53. In brief, MT-
4 cells were incubated with virus inoculum in 96 V-bottom well plates for 4 hr at 37°C after which the virus 
inoculum was washed away and replaced with fresh media. Immediately following removal of the virus 
inoculum and during the six subsequent days the quantity of virions present in the culture supernatant was 
quantified by measuring RT activity using a Q-PCR-based assay82. 
 
Biochemical analysis of virion core components in infected cells 
Biochemical analysis of retroviral cores in infected cells was performed as described previously56. Briefly, 
pgsA-745 cells were infected with VSV-G pseudotyped single cycle GFP-reporter viruses or its derivatives 
synchronously at 4°C. Following the removal of virus inoculum and extensive washes with PBS, cells were 
incubated at 37°C for 2 hr. To prevent loss of vRNA due to reverse-transcription, cells were infected in the 
presence of 25 μM nevirapine. Post-nuclear supernatants were separated by ultracentrifugation on 10-50% 
linear sucrose gradients using a Beckman SW55-Ti rotor at 30,000 rpm for 1 hr at 4°C. Ten 500 µl fractions 
from the top of the gradient were collected, and CA, IN, and vRNA in each fraction were analyzed by either 
immunoblotting or Q-PCR56. A SYBR-Green-based Q-PCR assay82 was used to determine RT activity in 






Visualization of vRNA in infected cells 
Viral RNA was visualized in infected cells according to the published multiplex immunofluorescent cell-
based detection of DNA, RNA and Protein (MICDDRP) protocol59. VSV-G pseudotyped HIV-1NL4-3 virus 
stocks were prepared as described above and concentrated 40X using a lentivirus precipitation solution 
(ALSTEM). PgsA-745 cells were plated on 1.5 mm collagen-treated coverslips (GG-12-1.5-Collagen, 
Neuvitro) placed in 24-well plates one day prior to infection. Synchronized infections were performed by 
incubating pre-chilled virus inoculum on the cells for 30 min at 4°C. Cells were infected with WT virus at 
a MOI of 0.5, or with an equivalent number (normalized by RNA copy number) of IN mutant viral particles. 
After removal of the virus inoculum cells were washed with PBS and either immediately fixed with 4% 
paraformaldehyde, or incubated at 37°C for 2 hr before fixing. To prevent loss of vRNA due to reverse-
transcription, cells were infected and incubated in the presence of 25 μM nevirapine. Following fixation, 
cells were dehydrated with ethanol and stored at -20°C. Prior to probing for vRNA, cells were rehydrated, 
incubated in 0.1% Tween in PBS for 10 min, and mounted on slides. Probing was performed using 
RNAScope probes and reagents (Advanced Cell Diagnostics). Briefly, coverslips were treated with protease 
solution for 15 min in a humidified HybEZ oven (Advanced Cell Diagnostics) at 40 °C. The coverslips 
were then washed with PBS and pre-designed anti-sense probes59 specific for HIV-1 vRNA were applied 
and allowed to hybridize with the samples in a humidified HybEZ oven at 40 °C for 2 hr. The probes were 
visualized by hybridizing with preamplifiers, amplifiers, and finally, a fluorescent label. First, pre-amplifier 
1 (Amp 1-FL) was hybridized to its cognate probe for 30 min in a humidified HybEZ oven at 40 °C. Samples 
were then subsequently incubated with Amp 2-FL, Amp 3-FL, and Amp 4A-FL for 15 min, 30 min, and 15 
min respectively. Between adding amplifiers, the coverslips were washed with a proprietary wash buffer. 
Nuclei were stained with DAPI diluted in PBS at room temperature for 5 min. Finally, coverslips were 






Microscopy and image quantification 
Images were taken using a Zeiss LSM 880 Airyscan confocal microscope equipped with a ×63/1.4 oil-
immersion objective using the Airyscan super-resolution mode. 10 images were taken for each sample using 
the ×63 objective. Numbers of nuclei and vRNA punctae in images were counted using Volocity software 
(Quorum Technologies). The number of vRNA punctae per 100 nuclei were recorded at 0 hr post-infection 
(hpi) and 2 hpi for each virus, and the number at 2 hpi compared to the number at 0 hpi.  
 
Analysis of the fate of vRNA genome in MT4 cells 
MT-4 cells were infected with VSV-G pseudotyped HIV-1 NL4-3 WT or equivalent number of mutant 
viruses (normalized by RT activity) synchronously at 4°C. After removal of virus inoculum and extensive 
washes with PBS, cells were incubated at 37°C for 6 hr in the presence of 25 μM nevirapine. Immediately 
after synchronization (0 h) and at 2 and 6 hr post-infection samples were taken from the infected cultures 





We thank Dr. Michael Malim for providing the anti-IN monoclonal antibody. We also thank Wandy 
Beatty for providing technical support and assistance with confocal microscopy. This study was 
supported by grants NIH grants P50 GM103297 (the Center for HIV RNA Studies) and GM122458 to 
SBK, AI143389-F31 fellowship to JE, R01 AI062520 to MK and SBK, U54 AI150472 to MK and AE, 







3.7 SUPPLEMENTAL FIGURES 
 
Figure 1-Figure Supplement 1. Expression of Vpr-IN fusion constructs. Representative immunoblot 
analysis of Vpr-IN fusion constructs in cell lysates. HEK293T cells were co-transfected with the HIV-1NL4-
3 IND116N proviral plasmid along with Vpr-IN expression plasmids encoding for the indicated IN 
substitutions or an empty vector control.  Expression of Vpr-IN constructs in cell lysates was detected using 
an anti-IN antibody. 
 
 
Figure 2-Figure Supplement 1. Premature loss of vRNA and IN from class II IN mutant viruses upon 
infection of target cells. (A) Representative images of uninfected pgsA-745 cells and cells infected with 
WT HIV-1NL4-3 viruses at 0 hpi. Cells were fixed and stained for vRNA (green) and nuclei (blue). (B) 
Representative images of pgsA745 cells infected with IN mutant HIV-1NL4-3 viruses 0 and 2 hpi. Cells were 
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This dissertation examines the mechanisms by which the HIV-1 integrase enzyme (IN) contributes to 
virion morphogenesis and viral replication independent of its function in integration. The findings 
presented in Chapter 2 demonstrate that IN ensures proper packaging of the HIV-1 RNA genome (vRNA) 
within the viral capsid via its binding to vRNA, and that IN-RNA binding requires proper IN 
multimerization. The data presented in Chapter 3 provides evidence that improperly formed viral particles 
generated by IN mutations are unable to replicate in target cells due to the premature loss of the exposed 
vRNA and IN. Collectively, these studies illuminate the vital role of the of IN in virion morphogenesis 
and the viral life cycle independent of its canonical role in integration. 
 
IN-RNA interaction accounts for the role of IN in virion morphogenesis 
Early mutagenesis studies have found that multiple substitutions in IN (class II mutations) lead to the 
generation of eccentric viral particles with the viral ribonucleoprotein complex (vRNP) consisting of the 
vRNA and nucleocapsid protein (NC) mislocalized outside of the capsid1-6. These obsvertaions provided 
the first hints that IN played a key role in virion maturation. However, a mechanistic explanation for why 
IN is crucial for proper particle formation remained elusive until the recent discovery that IN binds vRNA 
in virions at its CTD, and that preventing IN-RNA binding leads to the generation of eccentric viral 
particles7. This finding argued that IN mediates the correct placement of vRNA within the capsid through 
is interaction with vRNA; however, it remained unanswered how various mutations along the length of 
IN (class II mutations) cause the same morphological defects in virions despite being distally located 
from the RNA-binding site in the IN CTD. Our findings in Chapter 2 demonstrate that all class II IN 
mutations examined prevent IN-RNA binding in virions, and do so by one of three mechanisms; i.) by 
reducing the levels of IN in virions and precluding the formation of IN-RNA complexes; ii.) by 
interfering with proper IN multimerization and thereby indirectly preventing IN binding RNA; iii.) by 
directly preventing IN-RNA binding without affecting IN levels or multimerization. We further show that 
IN binds RNA as a tetramer, and that tetramerization is likely required to the binding and condensation of 
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vRNA during virion maturation. Our results cement the conclusion that IN-RNA binding accounts for the 
role of IN in virion morphogenesis, and provide mechanistic insight on how IN binds RNA. 
 
vRNA and IN from class II IN mutant viruses are prematurely lost from target cells  
Eccentric viral particles are non-infectious, and are blocked at or prior to the reverse transcription step in 
target cells1,3,5-35. Our findings in Chapter 3 reveal that in cells infected with class II IN mutant viruses 
vRNA and IN are prematurely lost. In addition, there was a spatial separation of reverse transcriptase 
(RT) from vRNA. Either the loss of the vRNA genome or its separation from RT would prevent 
successful reverse transcription and further viral replication. In addition, the loss of IN would prevent the 
downstream integration of the reverse-transcribed vDNA into the host DNA. Finally, we show that the 
loss of vRNA occurs after viral entry. Our results provide an explanation for why eccentric viral particles 
are defective for reverse transcription and unable to complete the HIV-1 life cycle, and suggest that the 
viral capsid is necessary to protect vRNA and IN after entry into the target cell. 
 
4.2 FUTURE INVESTIGATIONS 
Temporal assessment of IN-RNA interaction during virion morphogenesis 
The original discovery that HIV-1 IN binds viral genomic RNA in virions7 together with the evidence 
presented in Chapter 2 support the conclusion that IN contributes to proper virion maturation through its 
interaction with RNA. However, the temporal events during the maturation process and exactly when IN 
begins to interact with RNA remains unclear. As reviewed in Chapter 1, IN is synthesized as a domain of 
the Gag-Pol precursor polyprotein, and does not exist as an independent protein until it is cleaved by PR 
during virion maturation. It remains unanswered whether the IN domain can bind RNA in the context of 
the Gag-Pol precursor in cells or immature virions, or whether it must first be cleaved by PR. To 
determine if IN binds RNA in infected producer cells or immature virions, future studies will utilize a full 
length NL4-3 proviral clone lacking PR and with Factor Xa cleavage sites inserted in the Gag-Pol 
polyprotein around the IN domain. In the absence of PR, the Gag and Gag-Pol polyproteins will not be 
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cleaved and virions will remain trapped in an immature state after budding. In order to liberate the IN 
domain from the rest of Gag-Pol, cell and virion lysates will be treated with Factor Xa. The then separated 
IN domain can then be immunoprecipitated, along with any bound RNA. This approach will be combined 
with CLIP36 to immunoprecipiate IN and  determine if the IN domain of Gag-Pol binds RNA in the 
producer cells or immature virions. 
Previous studies4 and the data presented in Chapter 2 (Figure 6) demonstrate that deleting IN 
entirely results in the formation of both eccentric and immature viral particles. As the immature particles 
produced by the IN-deleted virus appear morphologically similar to immature WT viral particles before 
maturation, I predict that IN is not necessary for correct morphogenesis until the maturation step, and that 
IN does not interact with RNA until it is cleaved from the Gag-Pol precursor polyprotein. If this is the 
case, no vRNA should coimmunoprecipitate with the IN domain from producer cells or immature virions. 
However, if the proposed CLIP experiments do demonstrate that the IN domain of Gag-Pol binds vRNA 
in producer cells or immature virions, next-generation RNA sequencing as detailed in the CLIP protocol36 
will be used to determine the regions of vRNA bound by IN and identify any secondary structures or 
sequence motifs.  
 
Localization of IN in eccentric viral particles 
The results of the experiments presented in Chapter 3 (Figure 2) show that in target cells infected with 
class II IN mutant viruses IN itself is lost along with viral RNA, while data from Chapter 2 (Figure 7) 
shows that in a few class II IN mutant viruses IN becomes separated from the rest of the viral core when 
viral particle components are separated over linear sucrose gradients, suggesting that IN may also be 
mislocalized in the viral particles. However, in the majority of class II IN viruses IN migrated over the 
sucrose gradients similarly to the WT, and so it remains unclear if IN is located within or outside the 
capsid in mutant viral particles. 
 In contrast to vRNA which can be clearly visualized in virions using transmission electron 
microscopy (TEM), IN is not easily visualized by TEM and determining its exact localization within viral 
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particles is challenging. Attempts to label and visualize IN in viral particles using immuno electron 
microscopy (immune EM) were not successful, and so we next attempted to explain why IN migrates the 
way it does over the sucrose gradients. Neither destabilizing the viral capsid (Chapter 2, Figure 7 -Figure 
Supplement 1A) nor generation of virions devoid of RNA (Chapter 2, Figure 7 -Figure Supplement 1B) 
affected how IN migrated over linear sucrose gradients, indicating that the migration of IN over the 
gradients is independent of its being enclosed in an intact capsid or its being bound to RNA. However, 
these results do not offer any further insight into where IN is located in viral particles. While tagging IN 
often adversely affects viral fitness, one paper reports successfully labelling IN with and HA tag37, 
allowing for IN to be labeled in infected cells using immune EM. Future investigation of where IN is 
located in viral particles could employ a similar strategy. 
 
Conservation of IN-RNA interaction across different retroviruses 
Although all retroviruses initially produce immature viral particles that undergo a maturation process 
shortly after budding from the infected cell38, there is considerable variation in the morphologies of the 
mature capsids39,40. Whether IN plays a role in virion maturation in other retroviruses has not been 
investigated. Intriguingly, mutations in the C-terminal domain of the murine leukemia virus (MLV) IN 
prevent reverse transcription in target cells similar to class II mutations in HIV-141,42. More study is 
needed to determine if IN contributes to proper virion maturation in other retroviruses, and if IN does so 
by binding to RNA. Future research will use the previously mentioned CLIP protocol36 to determine if IN 
binds vRNA in mature virions of other retroviruses, and will test if inhibiting IN-RNA interactions leads 
to the generation of morphologically aberrant viral particles. 
 
Defining mechanisms responsible for the loss of vRNA and IN in target cells 
In Chapter 3 we demonstrate that both vRNA and IN are prematurely lost from target cells infected with 
class II IN mutant viruses. In addition, vRNA becomes spatially separated form RT. Either the loss of 
vRNA or its separation from RT would be sufficient to prevent reverse transcription and further viral 
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replication. TEM experiments clearly show that vRNA is mislocalized outsde the capsid in class II IN 
mutant viruses (Chapter 2, Figure 6), and when lysates from infected cells are separated over sucrose 
gradients RT comigrates with the viral capsid (CA) protein (Chapter 3, Figure 2), suggesting that RT is 
retained inside the viral capsid. However, we do not further define mechanisms responsible for the loss 
vRNA and IN.  
We have previously shown that proteasomal inhibition does not rescue vRNA and IN in target 
cells infected with eccentric particles generated by treatment with an allosteric integrase inhibitor 
(ALLINI) or the IN R269A/K273A mutation43, and I suspect that the loss of vRNA and IN is proteasome-
independent in other class II IN mutant viruses as well. However, the loss of vRNA can be rescued by 
preventing viral entry (Chapter 3, Figure 3B), indicating that a cellular mechanism may be involved. A 
possible candidate is the autophagy pathway, which has been implicated in the degradation of other HIV-
1 proteins44. Future investigation may test if the loss of vRNA and IN is dependent on autophagy by 
infecting cells with class II IN mutant viruses in the presence of an autophagy inhibitors such as 
chloroquine or anti-proteases. 
 
Determining the fate of CA mutant viral particles 
Mutations in IN or treatment with ALLINI’s disrupt virion morphogenesis and lead to the creation of 
eccentric viral particles that are blocked at reverse transcription in target cells. However, treating producer 
cells with compounds that target the viral CA protein itself can also lead to the generation of 
morphologically eccentric viral particles45. In addition, mutations in CA that destabilize the capsid lattice 
in vitro also block viral replication at reverse transcription46-49. The similar defects in both IN and CA 
mutant viruses suggest a shared underlying causal mechanism, and it is reasonable to imagine that either 
the mislocalization of the vRNA outside the capsid or the instability of the capsid after viral entry into the 
target cell may leave the vRNA exposed and vulnerable to loss or degradation. Ongoing experiments with 
CA mutant viruses have found that mutations that destabilize the capsid lattice also lead to the premature 
loss of vRNA and IN in target cells, similar to class II IN mutants50. Further investigation could focus on 
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identifying the mechanisms responsible for the loss of vRNA and IN, and test if they are the same 
mechanisms behind the loss of vRNA and IN in cells infected with class II IN mutant viruses. 
 
Immune consequences of eccentric morphology 
The capsid lattice is proposed not only to protect the vRNA and replicative enzymes from the host 
environment, but also to conceal the virus from immune recognition51. Cells are equipped with multiple 
cytosolic pattern recognition receptors (PRRs) capable of detecting viral RNA and DNA, and several 
PRRs including RIG-I52 and cGAS53 have been implemented in the sensing of HIV-1 nucleic acids. 
Transfecting purified HIV-1 RNA into peripheral blood mononuclear cells activates the NF-kB, p38, and 
IRF signaling pathways and elicits innate immune cytokine expression52, demonstrating that HIV-1 RNA 
does have the potential to trigger a cell-intrinsic innate immune response. Whether the mislocalization of 
the vRNA outside of the capsid lattice in eccentric viral particles allows for the vRNA to be sensed and 
initiates immune activation in the host cell is unclear. It is conceivable that infection with eccentric viral 
particles may result in immune activation. Conversely, it is also possible that exposed HIV-1 vRNA is 
lost or degraded too quickly to adequately trigger an immune response. Much work remains to be done to 
determine whether infection with eccentric HIV-1 viral particles has any immune consequences. 
Considering that disrupting virion morphogenesis and generating non-infectious, morphologically 
eccentric viral particles may be a valuable therapeutic strategy, it will be important to know how the host 
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